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There exists increasing concern that the Dietary Supplements Health and
Education Act ("DSHEA") has proven ineffective and perhaps counterproductive.
Most illustratively, consider a recent and remarkably candid remark from Tommy
Thompson, then Secretary of Health and Human Services: "I really think Congress
should take a look at the food supplement law again. It doesn't make any sense to
me."
A health law that makes no sense to the Secretary of Health of Health and
Human Services should certainly draw the attention of academics and policy-makers
alike. Much of the debate concerning DSHEA regards the disparity in legislative
treatment between dietary supplements, foods, and pharmaceutical drugs.
Specifically, while pharmaceutical drugs must undergo years of costly pre-market
testing, most dietary supplements-like most foods-can immediately enter the
market, and only after repeated instances of adverse reactions can the Food and Drug
Administration ("FDA") remove them. Such a framework appears to belie both
consumer expectations and marketing strategies, as dietary supplements tend to be
most perceived for their apparent medicinal qualities. Similar then to a dangerous
street intersection that awaits a tragic accident before town officials install a traffic
light, an unsafe dietary supplement awaits a tragic consumer reaction before the
FDA may respond. This philosophy of waiting for a foreseeable harm strikes many
as unnecessary, inefficient, and perhaps immoral.
On the other hand, many dietary supplements have proven not only safe, but
reasonably effective. While significant media attention has been directed toward the
minority of instances where dietary supplements have caused harm, less attention
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has been paid to the more repeated occurrences of either benign or helpful
supplements. Moreover, before policy-makers mandate extensive pre-market testing
of all dietary supplements, consider the likely effect on production: a certain
percentage of dietary supplement makers will find the economics of production too
costly and will thus leave the market. Granted, foreign markets for supplements
might still provide the requisite incentives for production, but a more costly entrance
fee into the U.S. market would clearly deter some level of production and convince a
number of makers to leave the market altogether. Equally troubling, companies
which choose to remain in the market would presumably pass on a portion of the
increased costs to consumers, who often bear the costs of heightened regulation.
Consequently, many beneficial dietary supplements would be priced out of the reach
of lower and middle income consumers who either have become users of those
products or could become users.
The issue then is one of nuance. Rather than sweeping regulatory intervention,
perhaps more carefully-tailored alterations would prove most desirable. This
philosophy appears desirable given informational deficiencies among dietary
supplement consumers, particularly those with cognitive biases that are easily
exploited by supplement manufacturers. Promisingly, such deficiencies may be
ameliorated through low-cost measures that promote enhanced communication of
product characteristics.
For these reasons, this Article proposes a refined approach to dietary
supplement labeling that would legally distinguish them on the basis of potential risk
and anticipated benefit. Indeed, the existing legal construct of the phrase "dietary
supplements" is both curious and overly simplistic. It includes minerals, vitamins,
herbs, botanical extracts, and amino acids-in other words, items that are not only
functionally different, but which might also present radically different risks and
benefits. Along those lines, the very consumers of dietary supplements should be
more carefully distinguished. For example, a person who digests Cortislim, a
controversial weight-loss supplement containing a murky mixture of vanadium,
chromium and botanical extracts, probably subscribes to a different risk and benefit
calculation than one who fancies Ricola cough drops. A more calibrated legal
framework would recognize those varying calculations.
How might such a revised communicatory model work without precipitating
material price increases or deterring beneficial dietary supplement production? One
method would entail more carefully-contemplated labeling requirements for dietary
supplements. Such requirements should enhance consumer risk-assessment and
reward reputable supplement manufacturers. To accomplish these goals, labels
should reveal potential interactions with pharmaceutical drugs and other
supplements, warnings of over-usage, predictable distinctions between "health"
claims and "structure/function" claims, and a recommended intake range based on
age and gender, among other personal characteristics. Of similar benefit would be
assured ingredient content, as well as greater coordination between the FDA and the
Federal Trade Commission ("FTC") in regulating false or misleading dietary
supplement claims. Importantly, because such labeling requirements would merely
require enhanced informational disclosure, they would impose only minimal cost
increases to manufacturing research, development, and production.
A second method would require dietary supplement manufacturers to register
ingredient contents with the FDA and to report adverse reactions to all products.
These two concepts are related in practice and in form to enhanced labeling
disclosure and would remedy a framework whereby the FDA fails to learn of over 99
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percent of adverse consumer reactions and cannot determine the ingredients in
nearly one third of those supplements that trigger adverse reactions. Requiring such
registration and reporting appears consistent with efficient modeling, particularly
given the FDA's limited resources; for the FDA to pursue information already
possessed by manufacturers appears wasteful and unnecessary. In addition to
providing consumers with more timely and crucial information to use when making
consumption choices, such requirements would also enhance lines of communication
between the FDA and manufacturers, as industry and governmental actors would
share product information. This in turn would enhance the reliability of adverse
event reporting and offer promise for greater industry-governmental relations.
Moreover, like enhanced labeling, registration and reporting are low-cost,
informational directives that preserve the production incentives and pricing schemes
of dietary supplement manufacturers.
Imposing such informational duties on dietary supplement manufacturing would
enhance consumer information, as well as the level of informed risk and assessable
benefit. Moreover, by avoiding incentive-altering regulation, such as pre-market
testing of dietary supplements, production incentives would remain intact,
particularly for those who sell verifiable products. Prices for such products should
also remain within reach of current and future clientele. In addition, by calibrating
dietary supplement information, consumer confidence in the much-maligned dietary
supplement industry should rise, thus offering a corresponding benefit to
manufacturers. Better informed consumers and more legitimized products would
also supply manufacturers with additional protection from product liability claims.
In exploring these ideas, this Article will canvass the dietary supplement
industry and explore how consumers of dietary supplements often experience
deleterious consequences of cognitive biases, particularly those manipulated by
manufacturers. At the same time, this Article will identify consumer benefits
derived from dietary supplement consumption, even when such benefits cannot be
"clinically" validated. This Article will also examine the salience of legislative
choice in promulgating dietary supplement laws, especially as it pertains to
communication of risk and benefit. In doing so, this Article will incorporate a
comparative approach, including a comparison to European models of consumerism
in the dietary supplements context. Lastly, this Article will examine the prescription
of new informational duties for dietary supplement manufacturers and how such
duties might enhance consumer choice without deterring production.
II. THE DIETARY SUPPLEMENT MARKET & ITS INTERACTION WITH
CONSUMER RISK
A. EXPLORING THE DIETARY SUPPLEMENT MARKET
The term "dietary supplement" comprises a strikingly large and diverse class of
products under one convenient rubric. Consider a working list of dietary
supplements compiled by the FDA: vitamins, essential minerals, protein, amino
acids, herbs, animal and plant extracts (e.g., garlic extracts and inert glandulars), fats
and lipid substances (e.g., fish oils, sterols, and essential fatty acids), dietary fibers,
and chemical compounds that may have biological activity but that are generally not
recognized as nutrients under the traditional definition of that term (e.g.,
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bioflavonoids, enzymes, nucleic acids, para-aminobenzoic acid, and rutin).2
Together, these and other substances comprise the nearly 29,000 dietary
supplements available for sale in the United States.3
Dietary supplements are distributed in a variety of instruments, most often
capsules, tablets, liquids, or powders.4 For this reason, some resemble medicines,
particularly when packaged in containers that indicate expiration dates or lot
numbers or that utilize cotton fillers, tamper proof caps, and other suggestive
characteristics. 5 Moreover, given the abundance of dietary supplement products,
many appear similar in packaging but offer disparate functions, risks, and benefits.
6
The dietary supplement industry has more than quadrupled in size since the
passage of DSHEA in 1994. More specifically, the industry recorded $20.1 billion
in sales in 2003, 7 up from $18.8 billion in 20028 and $17.8 billion in 2001. 9 In fact,
industry sales have appreciated over 400 percent from $4 billion in 1994. I°
Moreover, to place the $20.1 billion dietary supplement industry sales figure in
perspective, consider the following industry sales figures, also from 2003: candy
industry ($1.99 billion);"1 videogame industry ($10.0 billion); 12 organic food
industry ($10.8 billion); 13 toy industry ($20.7 billion); 14 and the restaurant industry
($440.1 billion). 15 Absent significant regulatory changes, the dietary supplement
industry anticipates continued, high-rate growth for an indefinite period of time.16
2 Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,692 (proposed June 18, 1993)
(to be codified at 21 C.F.R. Ch. I).
3 See Adverse Events Associated with Dietary Supplements: An Observational Study, 361
LANCET 101 (2003).
4 Other instruments include powders, teas, loose plant parts, and lozenges. Id.
5 58 Fed. Reg. at 33,692; see also William J. Skinner, Allowable Advertising Claims for
Dietary Supplements, 5 J. PHARMACY & L. 309, 310 (1994) (noting that labels for homeopathic
supplements appear strikingly similar to those for medicinal cold and flu products).
6 Consumers can easily confuse black or green tea with "dieter's teas" advertised for weight
loss. Dieter's teas are considered potentially harmful by the FDA. See Teri Capriotti, Any science
Behind the Hype of 'Natural' Dietary Supplements?, 5 MED/SURG NURSING 339 (2004).
7 Herbal Supplements: Studies Show Dangerous Interactions with RX, Drugs, AM. HEALTH
LINE, June 23, 2004, available at LEXIS, News Database.
8 Use of Dietary Supplements by Children: Testimony Before the House Energy and
Commerce Comm., FED. DOc. CLEARING HOUSE CONG. TESTIMONY, June 16, 2004 (statement of
Howard Beales, Director, Bureau of Consumer Protection), available at LEXIS, Nexis Library,
CNGTST file [hereinafter Statement of Howard Bealesi.
9 Andrea Combs, Dietary Supplements Promise Results, Still Dubious, CBS MARKETWATCH,
May 7, 2003, available at LEXIS, News Library, MKTWTC file.
10 See Chris Money, Teen herbicide: Dietary Supplements can be Deadly. So Why are They
Being Marketed to Kids?, 28 MOTHER JONES, May 1, 2003, at 18.
It Christine Laue, Sweet Indulgence Some Fear the Accessibility of Candy Around Halloween,
but Others See It As Just Part of the Fun, OMAHA WORLD-HERALD, Oct. 19, 2004, at O1E.
12 Elizabeth Leis, Toys are still for Playing, CAPITAL, Dec. 20, 2004, at Al.
13 Andrew Martin, Organic Milk Debate, CHI. TRIB., Jan. 10, 2005, at 1.
14 Leis, supra note 14.
1S Robin Davis, Deli Day, COLUMBUS DISPATCH, Sept. 29, 2004, at 01 B.
16 Julie Deardorff, Sitting Pretty, CHI. TRIB., Jan. 25, 2004, at I (citing PAUL ZANE PILZER,
THE WELLNESS REVOLUTION (2004)); see also StockSplits.com Announces 12 to 20 Plus Has Received
Approval From Its Shareholders for a I for 57 Reverse Split, MARKET WIRE, Nov. 4, 2004, available
at LEXIS News Database (projecting that retail sales in the dietary supplement market are expected to
reach $21 billion by year 2007, according to Frost & Sullivan reports). But see Amy Klien, Diet
Additive Seller Must Repay Millions, RECORD, July 13, 2004, at Al (noting that recent litigation
against dietary supplement manufacturers has damaged the industry's reputation).
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On the other hand, some external observers are skeptical of such anticipated
growth, reasoning that recent litigation has irreparably damaged the industry's
reputation. 17
The proportion of Americans using dietary supplements has grown in tandem
with surging sales. Indeed, approximately 60 percent of U.S. adults regularly use
dietary supplements, a percentage which has escalated considerably since the
passage of DSHEA. 18  Similar growth patterns have also emerged amongst
children. 19
Growing sales and the widening class of dietary supplement consumers have
invited inquiry about these products' popularity. Dietary supplements appear
attractive for several reasons. Many consumers gravitate to supplements that
promise to help them lose weight or "regain lost vigor" without requiring physical
exertion or dieting.20  Certain supplements can also induce effects similar to
prescription medicines but retail without required prescriptions and often at
markedly lower prices.21 Still other consumers take supplements as substitutes for
indigestible foods flush in nutrients; this is especially apparent among persons who
cannot digest dairy products. 22 Moreover, as many as two out of five consumers
take vitamin supplements everyday.2 3 There are also consumers who simply prefer
holistic and natural products to traditional medicines. Such preferences often reflect
individualistic predilections, such as distrust of modern medicine or appreciation of
"wholesome" or "earthly" substances. 24 Similarly, some consumers use supplements
for cultural and ethnic practices,25 as well as for emotional and psychological
needs.26
17 See, e.g., id.
18 FDA Holds Public Meeting About Safety of Dietary Supplements (National Public Radio
broadcast, Nov. 15, 2004), available at LEXIS, News Library, NPR file. But see Darshak Sanghavi, A
Mainstream Doctor Finds a Place for Alternative Medicine, BOSTON GLOBE, June 22, 2004, at CI
(citing a study conducted by JAMA, which concluded that 42 percent of Americans use dietary
supplements).
19 The market for children's supplements has also been growing. Industry analysts estimate
annual sales of children's supplements reached $510 million as of July 2002 and represented one of
the top niche markets in the supplement industry. Statement of Howard Beales, supra note 8.
20 For example, Zantrex-3, which includes caffeine, ginseng, and cocoa nut, has become
especially popular as a supplement which helps people lose weight and regain energy. Moreover, its
popularity has only increased since the FDA banned ephedra. See Carey Hamilton, Ephedra Ban Tilts
Diet Pill Market, SALT LAKE TRIB., Apr. 26, 2004, at Al.
21 See, e.g., Melissa Martinez, Often-crippling Arthritis Pain Has Led Many Sufferers on a
Search for a Cure, EL PASO TIMES, Mar. 6, 2000, at 1.
22 See Holly Weaver Beason, What to Do When Milk Isn't Your Pal, CHI. SUN-TiMES, Oct. 27,
1999, at S13.
23 Jennifer Harper, Japanese Find 1st New Vitamin in 55 Years, WASH. POST, Apr. 28, 2003,
at A03 (citing data the National Health and Nutrition Examination Survey, conducted by the
University of Wisconsin in 2001, that about 40 percent of Americans take vitamins regularly); see
also Paul L. Geltman et al., Daily Multivitamins With Iron to Prevent Anemia in High-Risk Infants: A
Randomized Clinical Trial, 114 PEDIATRICS 86 (2004) (finding that 41 percent of parents give their
children vitamins everyday, and 22 percent do so "usually").
24 Paige Hewitt, Focus: Vaccinations, HOUS. CHRON., July 30, 2003, at A22.
25 See, e.g., Alan R. Clough et al., Liver Function Test Abnormalities in Users of Aqueous
Kava Extracts, 6 J. ToxICOLOGY 821 (2003) (explaining that some consumers take Kava in adherence
to local cultural practices).
26 See, e.g., SuperCool St. John Launched for Emotional Well-Being, L. & HEALTH WEEKLY,
Aug. 14, 2004, at 31 (noting that consumers take St. John's Wort to help mood swings).
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B. COMPARING REGULATION OF DIETARY SUPPLEMENTS TO PHARMACEUTICAL
DRUGS & FOOD
Compared to drugs, dietary supplements and their labels appear strikingly
unregulated. Instead, dietary supplements are regulated more like food products.
Specifically, under DSHEA, the controlling legislation, most dietary supplements
become available to consumers without FDA review or approval, and in only limited
instances do novel ingredients receive pre-market evaluation for safety and
efficacy.2 7 Though seemingly benign, this pre-market arrangement proves slightly
more arduous than that imposed on food products, which may enter the stream of
commerce without FDA approval of specific ingredients, ingredient quantities, or
interactions between ingredients. Like food labels, however, dietary supplement
labels must list ingredients and levels of vitamins and minerals in a standardized
"Supplement Facts" panel. Manufacturers are afforded wide latitude in product
labeling and in product promotion; short of egregious misrepresentation or explicit
promise to cure disease, supplement manufacturers possess broad autonomy in how
they shepherd their product through the American economy.
28
For those who regard dietary supplements more like drugs than food products,
this absence of pre-market testing and stringent labeling requirements reflects a
peculiar deviation from norms within the medical and regulatory communities.
Indeed, compare dietary supplement regulation to that of pharmaceutical drugs.
29
Since passage of the Kefauver-Harris Amendment 30 in 1962, drugs must undergo
carefully designed clinical tests before becoming available to American consumers.
31
Clinical drug testing has been deemed essential to prevent dangerous and
inefficacious practices.32 The "New Drug Application" ("NDA") process is often
arduous and costly. Drug manufacturers may wait as long as thirteen years before
receiving FDA approval, during which time they may invest as much as $1.7 billion
in researching and testing.33 Even after such investment and wait, an application
may be denied for insufficient safety, inadequate testing, poor packaging, deficient
manufacturing, and lack of evidence that the drug will achieve its intended effect.34
In short, while dietary supplement manufacturers encounter a nearly unfettered path
to American consumers, drug manufacturers often travel a lengthy, costly, and
uncertain road to reach those same consumers.
27 For extensive analysis of DSHEA, see infra Part III.F.
28 Michael Cohen & Mary Ruggie, Integrating Complementary and Alternative Medical
Therapies in Conventional Medical Settings: Legal Quandaries and Potential Policy Models, 72 U.
CIN. L. REV. 671, 716 (2003).
29 Drugs are statutorily defined as "articles intended for use in the diagnosis, cure, mitigation,
treatment, or prevention of disease in man or other animals." 21 U.S.C. § 321(g)(1)(B) (2000).
30 21 U.S.C. § 355 (2000) (also known as the "Drug Efficacy Amendment").
31 For a more detailed discussion regarding the Kefauver-Harris Amendment, see Richard A.
Merrill, The Architecture of Government Regulation of Medical Products, 82 VA. L. REV. 1753, 1764-
69(1996).
32 See 21 C.F.R. § 312.23(a)(6)(iii)(b) (2004); see also Merrill, supra note 32, at 1782
(detailing clinical guidelines).
33 See RX Drugs: Development Costs $1.7 Billion Per Product, Study Says, AM. HEALTH
LINE, Dec. 8, 2003 (citing study conducted by Bain & Co. in 2003); see also Brian Varstag, Clinical
Trials to Receive a Boost, But How Big?, 286 JAMA 1303, 1304 (2001) (assessing the typical cost as
$500 million); Michael J. Malinowski, Legal Development: Globalization of Biotechnology and the
Public Health Challenges Accompanying It, 60 ALB. L. REV. 119, n. 179 (1996) (describing cost
structure for testing).
34 21 U.S.C. § 355.
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A further variance concerns labels. Unlike largely unregulated supplement
labels, which often express unrealistic claims and inaccurate content, drug labels are
highly scrutinized and thus carefully tailored, resulting in cautions and measured
claims.35  Indeed, since passage of the Federal Food, Drug and Cosmetic Act of
193836 ("FDCA") and subsequent regulations, drug manufacturers must label their
products with unambiguous directions and all-inclusive lists of warnings while
avoiding promotional language.37 The FDCA also requires that the sponsor of a
drug verify the safety and efficacy of each claim made in its labeling.38 Moreover,
drug manufacturers may only market their products for FDA approved uses; 39 any
marketing beyond such uses comprises "off-label" marketing, which the FDCA
prohibits.4 °
C. COGNITIVE BIASES AMONG DIETARY SUPPLEMENT CONSUMERS & MARKET
MANIPULATION
The existing regulatory treatment of dietary supplements has concerned policy-
makers in recent times, particularly as data has revealed that dietary supplement
consumers often perceive their consumption choice as one in lieu of drugs or other
medicines. Indeed, a recent study revealed that approximately 80 percent of
consumers who use dietary supplements purchase them instead of prescription drugs
or over-the-counter drugs. In another study, the two most cited consumer reasons
for taking supplements were "to feel better" (72 percent) and "to help prevent
getting sick" (67 percent).4' Most consumers also assume that dietary supplements
are qualitatively better than drugs: According to a third study, 56 percent of
consumers believe that supplements offer benefits comparable to those of drugs but
with fewer side effects, and 53 percent maintain that supplements often offer
benefits that conventional drugs cannot.42 Such data comports with the general
impression among clinicians that patients increasingly bypass consultations in favor
of self-medication through dietary supplements,43 as well as with long-standing
historical and global patterns of supplement use, particularly of herbs as medicines. 44
35 See Mara A. Michaels, FDA Regulation of Health Claims under the Nutrition Labeling and
Education Act of1990: A Proposal for a Less Restrictive Scientific Standard, 44 EMORY L.J. 319, 328
(1995).
36 Pub. L. No. 75-717, 52 Stat. 1040 (1938) (current version at 21 U.S.C. §§ 301- 397 (2000).
37 See, e.g., 21 C.F.R. §§ 201.56(a)-(b) (2004). Prior to enactment of the FDCA, a drug
manufacturer could set its own development and marketing schedule. If FDA disputed a drug's safety
or effectiveness, the agency bore the burden of initiating the legal process and proving that it was
dangerous or mislabeled. See Merrill, supra note 32, at 1797.
38 See id. at 1853 (exemplifying that if a manufacturer wished, implausibly, to market a drug
for the treatment of both high blood pressure and diabetes, it would need to submit to FDA sufficient
evidence that the drug was safe and effective for each "indication").
39 See id. at 1768.
40 See 21 U.S.C. §§ 331(a)-(b), 352 (2000).
41 See New Legislation Introduced to Allow Health Plan Coverage of Dietary Supplements,
PR NEWSWIRE, Sept. 4, 2001, available at LEXIS, News Library.
42 Id.
43 See, e.g., Arthur P. Grollman, professor of pharmacological sciences and medicine at the
State University of New York, Regulation of Dietary Drugs is Long Overdue, N.Y. TIMES, Feb. 23,
2003, at 10 (stating "[h]erbal products are primarily used as medicines"); see also Arnold I Friede,
Dietary Supplements: Background for Dialogue Between the Industry and Medical Profession, 53
FOOD DRUG L.J. 413, 419 (1998) (finding that consumers tend to choose self-medication through
dietary supplements whenever exposed to new health claims among dietary supplement products).
4 See Weishi Li, Botanical Drugs: A Future for Herbal Medicines, 19 J. CONTEMP. HEALTH
L. & POL'Y 117, 119 (2002); see also MICHAEL H. COHEN, BEYOND COMPLIMENTARY MEDICINE:
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Therefore, extensive regulatory variances between dietary supplements and drugs
appear disconsonant with consumer expectations.45
Moreover, dietary supplements are often marketed as medicinal products rather
than as food products.46 Likewise, supplement manufacturers sometimes obscure
distinction between their products and medicines through misleading product names,
such as the recently enjoined "Herbrozac," which, like the drug Prozac, claimed to
treat clinical depression among children.47 Similar concerns have been raised of the
supplement "herbal fen-phen," which sounds uncannily similar to the diet drug
combination fenfluramine and phentermine, commonly called "fen-phen.
4 8
These consumer purchasing patterns and advertising schemes appear even more
meaningful when considering that while many of the ingredients in dietary
supplements would prove safe in isolated form, certain ingredients may present
enhanced danger when offered in high concentrations or in chemical form. 4 9
Complicating matters, these ingredients are typically displayed on labels in
promotional ways that distort risk.5 °
LEGAL AND ETHICAL PERSPECTIVES ON HEALTH CARE AND HUMAN EVOLUTION (2000) (offering a
historical account of supplement usage, including usage as medicines); see also Regulation of Dietary
Supplements, 58 Fed. Reg. 33,690, 33,697-98 (proposed June 18, 1993) (finding that herbs have
traditionally been used as medicines).
45 Aside from popular recognition of their functional similarity, dietary supplements and
medicines have also been regarded as alike by members of Congress. For instance, in 2001, Senators
Tom Harkin and Orrin Hatch proposed the Dietary Supplement Tax Fairness Act, legislation that
would have amended Section 213(d) of the Internal Revenue Code of 1986, which limits the medical
expense deduction to prescribed drugs, to include spending on dietary supplements within the
definition of a medical expense. In introducing this legislation, Senator Harkin noted the need for
parity, arguing, "Our current policy is unfair and is failing to take full advantage of the potential to
improve health and hold down health care costs through preventive health care practices available to
consumers. Bringing the code up to date to recognize and allow for this important need for wellness
and health promotion is an important step forward to overall sound healthcare policy." See Statements
on Introduced Bills and Joint Resolutions, 147 Cong. Rec. S. 8709, Aug. 2, 2001. Also consider
similar remarks by Rep. Dan Burton: "Many consumers often ask why there are no insurance benefits
for dietary supplements, which are used primarily to maintain good health and wellness. Some dietary
supplements, like Folic Acid, can help prevent disease or disease risks like birth defects. Many
insurance companies would like to offer coverage to their beneficiaries who continually demand this
type of coverage. Unfortunately, the tax code does not allow an insurer to offer this coverage without
incurring tax liabilities to consumers and higher administration costs. This powerful disincentive
needs to be removed so health insurers can begin developing meaningful and cost effective benefits
for their beneficiaries and assist them in maintaining good health longer." See Extension of Remarks
by Rep. Burton, 147 Cong. Rec. E. 2288, Dec. 13, 2001.
46 See Kessler Criticizes Dietary Supplements, OMAHA WORLD-HERALD, Mar. 4, 1998,
available at LEXIS, News Library (citing remarks by former FDA Commissioner David Kessler, who
argued that dietary supplements are often marketed to confuse consumers into believing those
products possess medicinal qualities).
4 See Eli Lilly & Co. v. Natural Answers, Inc., 233 F.3d 456, (7th Cir. 2000) (affirming
enjoining use of defendant's mark under the Lanham Trademark Act, the Federal Trademark Dilution
Act and state unfair competition law); see also Liem Thanh Do, Dilution Standard Number: A
Quantitative Approach in Proving Actual Dilution under the Federal Trademark Dilution Act, 11 TEX.
WESLEYAN L. REV. 107, 128 (2004) (discussing the implications of the Eli Lilly holding).
48 See Marian Segal, FDA Warns Against Drug Promotion of "Herbal Fen-Phen ", FDA TALK
PAPER, Nov. 6, 1997, available at http://www.fda.gov/bbs/topics/ANSWERS/ANSOO832.html.
49 Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,692 (June 18, 1993); see also,
e.g., Bernard A. Schwetz, Safety of Aristolochic Acid, 285 JAMA 2705 (2001) (describing deleterious
consequences of aristolochic acid when dispensed in high concentrations).
50 58 Fed. Reg. at 33,692; see also Wayne B. Jonas, Alternative Medicine: Learning From the
Past, Examining the Present, Advancing to the Future, 280 JAMA 1616, 1618 (1999) (identifying
historical trends of dietary supplement labeling that have proved deleterious for consumers). Notably,
these phenomena appear exacerbated on the Internet with on-line vendors. See Charles A. Morris &
Jerry Avorn, Internet Marketing of Herbal Products, 290 JAMA 1505, 1509 (2003).
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Promotional concerns appear especially salient for consumers prone to
discounting product risk, such as economically-disadvantaged persons and children.
These are especially impressionable groups, and thus vulnerable to "myth-making"
among dietary supplements, whereby value is ascribed to reputational, rather than
scientific qualities.5 1 Indeed, despite the lack of clinical validation, many consumers
believe that certain supplements are "proven.' 52 For instance, garlic pills are said to
lower cholesterol; ginkgo allegedly helps one's memory; and Echinacea may
effectively treat flu symptoms. 53 To date, however, independent research has failed
to confirm any of these claims. 54 Thus, much like superstitions and folklore, dietary
supplements often enjoy more salience than objective data would suggest.
Optimism bias, or consumers' tendency to assume that general risks posed by
products do not apply with equal force to themselves,55 may offer a useful corollary
to myth-making. This is especially true since optimism bias tends to flourish when
risks are long-term or are presumed modifiable through behavior.56 Along those
lines, when consumers assume that signs of toxicity will appear early in product
usage, they tend to assume that an absence of such early signs foretells exemption
from future risk.57 For instance, smokers tend to perceive smoking as significantly
less risky for themselves than for other smokers.58 These effects are most
pronounced among children smokers, who often rate their own chances of
contracting lung disease as nearly identical to those of non-smokers.59
Myth-making and optimism bias among consumers are especially exploitable
characteristics. Indeed, when consumers systematically underestimate risk,
manufacturers may more readily conceal risk information.6 ° Conversely, when
positive images of product use repeatedly appear-such as an often-aired
infomercial of a slim man and woman consuming a particular diet pill-consumers
51 Elizabeth R. McGuire, The Entitlement of Veterans Affairs Medical Patients to Vulnerable
Population Status for Human Medical Research, 2 HEALTH MATRIX 259, 279-80 (1992).
52 See Doug Cutter, The 7 Myths of Dietary Supplements, RICH. TIMES DISPATCH, Jan. 21,
2004, at D-8.
53 See Combs, supra note 9.
54 See Alan D. Woolf, Herbal Remedies and Children: Do They Work? Are They Harmful?,
112 PEDIATRICS 240, 240-46 (2003); see also H. C. Bucher, Effects of dietary calcium
supplementation on blood pressure: A meta-analysis of randomized controlled trials, 275 JAMA
1016, 1022 (1996) (concluding that contrary to popular belief, calcium supplementation appears to
promote no appreciable reduction in blood pressure); Michael L. Macknin et. al, Zinc Gluconate
Lozenges for Treating the Common Cold in Children: A Randomized Controlled Trial, 279 JAMA
1962, 1967 (1998) (finding that zinc offers no clinical value in treating the common cold).
55 See Jon D. Hanson & Douglas A. Kysar, Taking Behavioralism Seriously: Some Evidence
of Market Manipulation, 112 HARV. L. REV. 1420, 1511 (1999).
56 See Jon D. Hanson & Douglas A. Kysar, Taking Behavioralism Seriously: The Problem of
Market Manipulation, 74 N.Y.U.L. Rev. 632, 657 (1999).
57 See Paul Slovic, Do Adolescent Smokers Know the Risks?, 47 DUKE L.J. 1133, 1137 (1998)
(citing Neil D. Weinstein, Unrealistic Optimism About Susceptibility to Health Problems: Conclusions
from a Community-Wide Sample, 10 J. BEHAV. MED. 481, 488 (1987)).
58 See Hanson & Kysar, supra note 55, at 1512; see also Suzanne C. Segerstrom et al.,
Optimistic Bias Among Cigarette Smokers, 23 J. APPLIED SOC. PSYCHOL. 1606, 1614-17 (1993);
Victor J. Strecher et al., Do Cigarette Smokers Have Unrealistic Perceptions of Their Heart Attack,
Cancer, and Stroke Risks?, 18 J. BEHAV. MED. 45, 49 (1995).
59 See Jonathan D. Reppucci et al., Unrealistic Optimism Among Adolescent Smokers and
Nonsmokers, 11 J. PRIMARY PREVENTION 227, 235 (1991). But see W. Kip Viscusi, Constructive
Cigarette Regulation, 47 DUKE L.J. 1095, 1113-14 (1998) (presenting evidence that optimism bias is
unsupported in the context of cigarette smoking).60See Hanson & Kysar, supra note 55, at 1514.
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tend to surmise unrealistically favorable expectations. 61 This is especially true when
short-term product use seldom results in injury, at least to consumers' physical
62
appearance.
Moreover, in the midst of the ephedra fallout, some dietary supplement
manufacturers have adroitly utilized the "irrelevant third option effect," whereby
they market their products as "ephedra free" and thus of apparent less-risk.63 When
any seller introduces irrelevant options, a consumer typically becomes biased in
favor of options that he originally disfavored. 64 Indeed, by framing the choice
between something dangerous, something much less risky, and no action at all,
supplement manufacturers may encourage new or continued use of supplements,
much like the option of "unfiltered" or "light" cigarettes encourages would-be
quitters to continue smoking.65
Individuals who lack significant resources are particularly vulnerable to choice
distortions among dietary supplements. Indeed, those without access to health care
often become heavy dietary supplement users. According to a December 2004 study
released by the non-profit, non-partisan Center for Studying Health System Change,
consumers who select supplements because they regard conventional treatments as
expensive are almost twice as likely to earn incomes below the poverty line,
significantly more likely to report poorer health status, and four times more likely to
be uninsured.66 Equally troubling, the most popular supplements among low-income
persons are those known to cause serious side effects, such as St. John's Wort and
Kava. 67 These consumption patterns are especially apparent among elderly persons
who cannot afford prescription drugs, as they have increasingly turned to less
expensive, but potentially dangerous, dietary supplements.68  For instance, many
seniors purchase anti-oxidants, such as vitamin E and beta-carotene, largely based
on the word-of-mouth belief that they prevent cancer. 69 Available data, however,
indicates no such discernable benefit; in stark contrast, those particular anti-oxidants
have been associated with increased risk of lung cancer among smokers.
70
61 See id.
62 Id. at 1515.
63 On May 18, 2005, a Google search of "ephedra free" yielded 421,000 results, and most of
those results directed to websites that promoted the sale of"ephedra free" diet pills.
64 See Hanson & Kysar, supra note 55, at 1440 (noting this effect with the sale of used cars).
65 A similar concept would be how the presence of a delicious and fattening dessert option
may encourage "would-be abstainers to order ice cream with fruit." Id. at 1515; see also Richard
Saltus, Tobacco Critics Say "Lite" Label Misleads, BOSTON GLOBE, Jan. 31, 1997, at B2 (noting
research that longtime smokers lose motivation to quit when they switch to lighter brands).
66 See HA T. Tu & J. LEE HARGRAVES, CTR. FOR STUDYING HEALTH SYS. CHANGE, DATA
BULLETIN No. 28: HIGH COST OF MEDICAL CARE PROMPTS CONSUMERS TO SEEK ALTERNATIVES
(2004), available at http://www.hschange.org/CONTENT/722/.
67 Id.
68 See Johanna T. Dwyer et al., Assessing Nutritional Status in Elderly Patients, 47 AM. FAM.
PHYSICIAN 63 (1993); see also Earl Lane, As More Seniors Turn to Supplements, More Data Needed,
MILWAUKEE J. SENTINEL, Feb. 3, 2004, at OIG (noting increasing trend of seniors to rely on dietary
supplements for medicinal needs).
69 See Rebecca H. Madley, Reviving the Antioxidant Market, Nutraceuticals World, at
http://www.nutraceuticalsworld.com/mar01 l.htm (last visited May 10, 2005).
70 See Lane, supra note 68 (citing comments by Susan Mayne, a Yale University
epidemiologist). On the other hand, preliminary, if inconclusive data suggests that Vitamin E can
improve the immune response to respiratory tract infections among the elderly. See Simin Nikbin
Meydani et al., Vitamin E and Respiratory Tract Infections in Elderly Nursing Home Residents, 292
JAMA 828, 836 (2004). Similarly promising, if premature, findings have identified a positive
correlation between Vitamin D consumption and reduced frequency of falling. See Heike A. Bischoff-
Ferrari et al., Effect of Vitamin D on Falls, 291 JAMA 1999, 2006 (2004).
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Adolescents are likewise malleable consumers of dietary supplements. This
malleability partly relates to general characteristics of persons in that age group, as
they have a greater tendency than adults to take dangerous risks, weigh short-term
consequences more heavily than long-term consequences, and act impulsively. 7'
Such phenomena are especially evident among older adolescents, who tend to
engage in risky and experimental behavior "as part of the process of separating from
family and becoming autonomous., 7 2 Moreover, adolescents often struggle with
discriminating fact from fiction 73 and are more likely than adults to uncritically
ascribe to advice or suggestion.74  Dietary supplement companies are also
presumably aware that young persons represent the most lucrative purchasing cohort
of any age group 75 and that their buying power has accelerated faster than that of any
other age group in recent years.
76
Data concerning dietary supplements use by student athletes uniquely
illuminates the adolescent tendency to discount risk. For instance, most college
athletes who use ephedra products became habitual users while playing sports in
high school.7 7 It is thought that ephedra and similar stimulants offer the "extra edge"
to perform, improve skill level, or help one become more athletic; 78 correspondingly,
many younger users are motivated by peer pressure 79 or quixotic sports aspirations.
80
Direct observations of supplement usage by role models only reinforce the
availability and desirability of these stimulants. Children and adolescents may
readily watch coaches, trainers, and teammates, as well as professional sports stars,
use and promote dietary supplements. 81  By forecasting unrealistic benefits and
71 See Thomas Grisso, The Competence of Adolescents as Trial Defendants, 3 PSYCH. PUB.
POL. & L. 3, 14; see also Barbara A. Atwood, The Child's Voice in Custody Litigation: An Empirical
Survey and Suggestions for Reform, 45 ARIZ. L. REV. 629, 657 (2003); David E. Arredondo, Child
Development, Children's Mental Health and the Juvenile Justice System: Principles for Effective
Decision-Making, 14 STAN. L. & POL'Y REV. 13, 15 (2003) (describing impulsive behavior of
adolescents).
72 See Barry C. Feld, Competence, Culpability, and Punishment: Implications of Atkins for
Executing and Sentencing Adolescents, 32 HOFSTRA L. REV. 463, 511 (2003); see also ERIK H.
ERIKSON, IDENTITY YOUTH AND CRISIS 156 (1968) (describing the appeal of risk to adolescents, since
it helps them find a role in society). Indeed, these phenomena help explain why "tobacco, alcohol,
and illicit drug use begin most often between the ages of sixteen and eighteen." Elizabeth Cauffman
& Laurence Steinberg, The Cognitive and Affective Influences on Adolescent Decision-Making, 68
TEMP. L. REV. 1763, 1767 (1995).
73 See Angela J. Campbell, Ads2Kids.com: Should Government Regulate Advertising to
Children on the World Wide Web?, 33 GONZ. L. REV. 311,320 (1997-1998).
74 See Atwood, supra note 71, at 657.
75 See JAMES U. MCNEAL, KIDS AS CUSTOMERS: A HANDBOOK OF MARKETING TO CHILDREN
1-20 (1992).
76 See Karen E. Rondon, Innovations and Trends in the Electronic Toy Market, at 10 (SRI
Consulting, Bus. Intelligence Program, No. D96-2028, 1996), available at http://www.sric-bi.com/;
see also David Barboza, If You Pitch It, They Will Eat It, N.Y. TIMES, Aug. 3, 2003, § 3, at I
(reporting that between their own spending and their influence on parental spending, children four- to
twelve-years-old are responsible for approximately $600 billion a year in expenditures).
77 See Money, supra note 10 (citing a study conducted by the NCAA).
78 See Steroids: Play Safe, Play Fair, American Academy of Pediatrics, at
http://www.aap.org/family/steroids.htm (last visited May 10, 2005).
79 See Cara B. Ebbeling et al., Childhood Obesity: Public-Health Crisis, Common Sense Cure,
360 LANCET 473, 476 (2002).
80 See generally Kelly Ann Kaczka, From Herbal Prozac to Mark McGuire's Tonic: How the
Dietary Supplement Health and Education Act Changed the Regulatory Landscape for Health
Products, 16 J. CONTEMP. HEALTH L. & POL'Y 463 (2000).
81 See Money, supra note 10.
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depreciating risks, these impressions and exigencies merely exacerbate myth-
believing and optimism bias among a particularly vulnerable group.
Of similar concern, adolescents and young adults appear increasingly interested
in creatine monohydrate supplements. These supplements elevate the body's supply
of a compound found in the liver, pancreas, and kidneys, which ultimately becomes
phosphocreatine, a source of energy for weight-lifting. 82 According to the American
Academy of Pediatrics, nearly 30 percent of college athletes use creatine, as do
nearly 20 percent of high school juniors and seniors. 83 More recently, non-athlete
students have become frequent creatine customers, apparently motivated by a desire
to look stronger and more attractive. 84 However, neither the safety nor efficacy of
creatine has been clinically determined, though commonly observed side effects
include cramping and gastrointestinal upset; less often, kidney dysfunction has been
reported.85
Perhaps more disturbing, use of creatine and similar products may encourage the
subsequent use of toxic and illegal substances, such as anabolic steroids. 86 Indeed,
the availability of such substances may endorse a socially-permissive attitude
towards external enhancements, which might encourage a more lenient attitude
toward steroid use.87 Separately, consider the salience of the irrelevant third option
effect in the creatine consumer model: by framing the choice between a steroid,
creatine, and no enhancement, manufacturers of creatine products likely encourage
would-be non-purchasers of steroids to purchase creatine.
88
Of course, distorted perceptions are not apparent solely among those of
economic disadvantage or those in their childhood and adolescent years. Rather,
consumers tend to assume a product's safety merely by virtue of the product's
placement on a store shelf, particularly at established retail chains. Other consumers
presumptively equate "natural" products with "harmless" products.89  Moreover,
because dietary supplement manufacturers may readily advance disingenuous
82 See Jordan D. Metzl et al., Creatine Use Among Young Athletes, 108 PEDIATRICS 421, 421-
22 (2001).
83 Id.
84 See Sameh Fahmy, Muscle Madness, THE TENNESSEAN, May 11, 2004, at ID (citing study
conducted by Dr. Nick Evans of the UCLA Medical Center and Los Angeles Orthopedic Hospital).
85 See Metzl et al., supra note 82; see also Kati Plax, Performance Enhances Pose Numerous
Risks, ST. Louis POST-DISPATCH, Oct. 4, 2004, at 8 (reporting side effects); Avi Salzman, Playing
Fields and the Threat of Steroid Use, N.Y. TIMES, Dec. 19, 2004, § 14CN, at I (providing additional
background information on appeal of creatine to children and adolescents).
86 See Jeremy Fowler, Clouds of Suspicion, ALBUQUERQUE TRIB., Nov. 27, 2004, at BI
(citing remarks by Professor Robert Robergs of the University of New Mexico, an expert on exercise
physiology).
87 See Metzl et al., supra note 82; see also Avi Salzman, Playing Fields and the Threat of
Steroid Use, N.Y. TIMES, Dec. 19, 2004, at I (providing additional background information on appeal
of creatine to children and adolescents). Not all studies identify health impairment with use of
creatine. See e.g., J.R. Poortmans & M. Franceux, Renal Dysfunction Accompanying Oral Creatine
Supplements, 352 LANCET 234 (1998) (concluding that "medium-term oral creatine supplements do
not affect kidney function in healthy individuals").
88 See supra note 65 and accompanying text.
89 See Brian F. McBride, Electrocardiographic and Hemodynamic Effects of a
Multicomponent Dietary Supplement Containing Ephedra and Caffeine: A Randomized Controlled
Trial, 291 JAMA 216, 221 (2004) (concluding that "consumers are drawn to herbal preparations
because of their nonprescription status, direct-to-consumer advertising, and the perception that natural
products are innately safe. Unfortunately, the perception of safety may be the result of a lack of
data"); see also Susan Okie, Dietary Supplements Gaining Public Approval, If Not Government's,
WASH. POST, Nov. 25, 1997, at AI (citing research conducted by Esther Sternberg, a rheumatologist
with the National Institute of Mental Health, suggesting that consumers overestimate the degree of
proven safety associated with dietary supplements).
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claims, they are able to utilize context-distortions to more generally mislead
consumers. For instance, supplements which claim to "boost metabolism" and
thereby facilitate bodybuilding often neglect to mention that only professional body-
builders enjoy meaningful benefit. 90
Similarly, consider the very real effect of celebrity product endorsements on
consumer evaluation of dietary supplements. Although celebrities usually lack the
requisite qualifications to knowledgeably dispense health-related advice, they are
nevertheless employed with great alacrity by dietary supplement manufacturers. For
instance, Phillip C. McGraw, Ph.D. (a.k.a. "Dr. Phil"), a trained psychologist but not
a medical doctor, endorses energy bars and multivitamin supplements.91  Less
credibly, self-help guru Anthony Robbins likewise endorses a brand of nutritional
supplements.92 Similarly, actor James Brolin, who once starred as a physician in the
television series "Marcus Welby, M.D.," now stars in promotions for a dietary
supplement claiming to mitigate arthritis. 93 Even unintentional endorsements have
proven salient: sales of Zantrex-3-a diet pill containing high doses of caffeine,
green tea, and three South American herbs-soared after pop star Brittany Spears
spilled a bottle of the product with photographers nearby. 94 Significantly, because
consumers tend to regard the dietary supplement market as confusing and daunting,
market experts find consumers are more likely to trust celebrity opinions of dietary
supplements than of more familiar products.
95
D. SUBJECTIVE CONSUMER VALUE ATTRIBUTABLE TO DIETARY SUPPLEMENTS
The preceding sections paint an admittedly dim view of dietary supplements and
their interaction with consumer choice. However, many dietary supplements have
proven effective, and, even without clinical validation, have achieved support within
the American medical community.9 6 This section will describe some of the more
favorable aspects of dietary supplements, and why efforts to curtail their sale must
be carefully tailored.
Proof of safety and effectiveness, at least in a clinical sense, is often hard to
establish for dietary supplements. Without requisite assurances of product safety or
stringent labeling guidelines, dietary supplement manufacturers lack the incentive to
conduct exhaustive testing. This is particularly true given fierce industry
90 See 'Revving Up' on Hooey, WASH. POST, Aug. 26, 2003, at F3 (quoting David Nieman,
director of the Human Performance Laboratory at Appalachian State University).
91 See Deardorff, supra note 16.
92 See id.
93 See Lifestyles of the Sick and Famous, ALAMEDA TIMES-STAR, Nov. 17, 2002, at
Opinions/Editorials. Brolin played Dr. Steven Kiley in the short-lived television series Marcus
Welby, MD. See INTERNET MOVIE DATABASE, PROFILE: JAMES BROLIN, available at
http://www.imdb.com/name/nm0000981/ (last visited Jan. 1, 2005).
94 See Michael Specter, Miracle in a Bottle, THE NEW YORKER, Feb. 2, 2004, at 64.
95 See Deardorff, supra note 16. Also consider that consumers may be confused by advice
from physicians concerning dietary supplements, as physicians tend to embrace widely varied views
of supplement efficacy. See Kenneth M. Davis et al., Physician Marketing of Nutritional
Supplements, 280 JAMA 967, 968 (1998). Accordingly, it would appear that "celebrity"
endorsements might achieve greater salience among consumers.
96 See Amber K. Spencer, Comment, The FDA Knows Best ... Or Does It? First Amendment
Protection of Health Claims on Dietary Supplements: Pearson v. Shalala, 15 BYU J. PUB. L. 87
(2000); see also Rachel Brand, Hauser Tumbles into Chapter 11, ROCKY MOUNTAIN NEWS, Apr. 3,
2003, at l1B (detailing how Hauser, a dietary supplement manufacturer, blamed "intense competition
in the dietary supplement industry" for its recent decision to declare bankruptcy).
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competition and the resulting "rush" to deliver products onto the market.97 Although
independent supplement watchdog groups, such as ConsumerLab.com, regularly test
dietary supplements for ingredient integrity and claim accuracy, such testing
typically occurs well after a product's introduction into the stream of commerce.
98
Predictably, the lack of uniform supplement testing often draws stern rebuke
from traditional medical providers, who employ clinical testing to distinguish not
only helpful from harmful products, but also modem from primitive medicines. 99
Clinical testing measures biological plausibility, consistency and reproducibility of
research, dose-response effects, strength of causal association, and correct
temporality between cause and effect.100 Accordingly, without clinical testing, there
exists considerable opportunity for unrealistic and deleterious practices, as well as
misinterpreted results. For instance, in some primitive tribal communities, medical
healers still treat AIDS with herbs.' 0' Despite using different herbs and dissimilar
methods of preparation, they nevertheless believe their methodologies are
effective. 0 2 Similarly, without rigorous testing, contaminants and adulterants within
supplements may pose unexpected danger. To illustrate, a recent seizure of 260
imported Chinese supplements by the California Department of Public Health
revealed that over half of the supplements contained high levels of lead and
arsenic. 103
Despite the absence of methodologically-deduced "proof," certain dietary
supplements have been heralded by consumers. The herb ginseng, for instance, has
been used for centuries by Tibetan people to improve endurance and memory; its
relatively recent introduction into the United States market has evinced similar
claims. 10 4 Likewise, many consumers of elderberry extract insist that it alleviates flu
97 See Amy Shipley, New Steroids Sold Over Counter, WASH. POST, Dec. 6, 2002, at Al
(describing incentive for copy-cat practices among dietary supplement manufacturers given fierce
market competition); see also Brand, supra note 96, at lB.
98 See Jane E. Allen, A First Step Toward Standardizing Supplements, L.A. TIMES, Mar. 17,
2003, at 3; see also infra Part V.B.
99 See Joseph A. Page, The Passage of Time: The Implications for Product Liability, 58
N.Y.U.L. REV. 853, 869 (1983); see also S. Weingarten, Practice Guidelines and Prediction Rules
Should be Subject to Careful Clinical Testing, 277 JAMA 1977, 1978 (1997) (describing significance
of clinical testing guidelines in the medical review process). Note that, in light of international
competition among drug manufacturers, the FDA has become arguably less demanding of American
manufacturers in regards to clinical testing and clinical trials. See Nigel S. B. Dawson,
Pharmacopolitics: Drug Regulation in the United States and Germany, 292 JAMA 742, 743 (2004).
105 See Marcia Angell & Jerome P. Kassirer, Alternative Medicine: The Risks of Untested and
Unregulated Remedies, 339 NEw ENG. J. MED. 839 (1998); see also Jerry Hurst et. al, Are Physicians'
Office Laboratory Results of Comparable Quality to Those Produced in Other Laboratory Settings?,
279 JAMA 468, 471 (1998) (distinguishing between varying clinical tests, including waived tests,
provider-performed microscopy, and moderate-complexity and high-complexity tests).
101 See Gerard Bodekar, A Regional Task Force on Traditional Medicine and AIDS, 355
LANCET 1284 (2000); see also Sanghavi, supra note 18 (illustrating lack of effectiveness among
herbal remedies for AIDS); Austin Kaluba, More Research Needed in Zambian Herbal Medicines,
TIMES ZAMBIA, Jan. 24, 2005, at I (describing use of herbs by Zambian medical healers).
102 Id.
103 See H.J. Kaltsas, Patent Poisons, ALTERN MED., Nov. 1999, at 24-28; see also Richard J.
Ko, Causes, Epidemiology, and Clinical Evaluation of Suspected Herbal Poisoning, 6 J. TOXICOLOGY
697 (1999) (explaining inconsistent quality controls of Chinese manufacturers, and how the central
government has limited authority and resources to regulate the dietary supplement industry).
104 See generally A Herb a Day Keeps Doctors Away, CHINA DAILY, Oct. 27, 2003, available
at LEXIS News Database. Recent data, however, suggests that ginseng may impair the absorption of
anticlotting drugs. See Mike Mitka, Study Reveals Ginseng Supplements May Hamper Effects of
Anticlotting Drug, 292 JAMA 674 (2004). It may also interfere with certain perioperative care
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symptoms. 0 5 Although these findings represent anecdotal and unscientific evidence,
they intimate that widespread clinical benefits may be associated with certain
supplements.
Consumer impressions are also significant because certain supplements may
subsequently receive clinical validation. For instance, scientists find that green tea
extract and Chinese Red Yeast Rice feature anticancer effects. 0 6  Perhaps most
dramatically, consider artemisinin, an ancient Chinese herbal compound based on
qinghasuu (sweet wormwood). Decades ago, Chinese doctors found that artemisinin
significantly reduced the death rate of malaria patients without imposing serious
side-effects.1 °7 For years, westernized medical communities dismissed artemisinin's
alleged prowess as mere mysticism.'0 8 However, as malaria evolved into resistant
strains against the drug Chloroquine, world health agencies reluctantly turned to the
herbal compound. 109 Later clinical studies have not only confirmed artemisinin's
effectiveness, but now generally regard it as superior to Chloroquine."
Along these lines, anthropological research may illuminate effective treatments
among traditional medicines where clinical testing does not."' Put differently, the
clinical value of historical, albeit circumstantial findings can reveal unique and
valuable information. For instance, consider the long-standing Laotian tradition of
incorporating herbs into meals." l2 Intriguingly, anthropologists find uncanny and
detailed knowledge among Laotians about the ways in which each herb benefits the
body, even though many Laotians lack formal education and even though such
conclusions were originally drawn centuries ago, long before westernized testing of
herbal efficacy."
13
procedures. See Michael K. Ang-Lee et al., Herbal Medicines and Perioperative Care, 286 JAMA
208, 216 (2001).
105 See Lisa Liddane, No Flu Shot?, KNIGHT RIDDER/TRIBUNE NEWS SERVICE, Nov. 12, 2004,
available at LEXIS News Database. Historically, elderberry has not always been associated with
positive medicinal effect. For instance, in 1984, eight Californians who consumed elderberry juice
suffered acute gastrointestinal and neurologic symptoms, resulting in one hospitalization. However,
such problems typically do not emerge when preparers of the juice remove the bits of leaves and
stems from the berries. See Elderberry Poisoning, 29 AM. FAM. PHYSICIAN 346 (1984).
106 See Diet, Physical Activity, and Dietary Supplements - the Scientific Basis For Improving
Health, Saving Money, and Preserving Personal Choice: Hearing Before the House Comm. on Gov't
Reform, 107th Cong. (July 25, 2002) (statement of Dr. David Heber, Director Division of Clinical Nutrition,
University of California). Recent data also suggests that Vitamin A supplements can lessen the severity of
hip fractures among older women. See Diane Feskanich, Vitamin A Intake and Hip Fractures Among
Postmenopausal Women, 287 JAMA 47, 54 (2002).
107 See Donald G. McNeil, Jr., Herbal Drug Widely Embraced In Treating Resistant Malaria,
N.Y. TIMES, May 10, 2004, at I (noting that, in one outbreak in Vietnam, artemisinin allegedly cut the
death rate by 97 percent).
108 See id.
109 See id
110 See N.J. White et al., Comparison of Artemether and Chloroquine for Severe Malaria in Gambian
Children, 339 LANCET 317-21 (1992); see also Rediscovering Wormwood: Qinghaosu for Malaria, 339
LANCET 649-51 (1992) (highlighting unexpectedness effectiveness of artemisinin); McNeil, supra note 107
(detailing how artemisinin has contained small outbreaks in mosquito-infested areas and prevented them
from becoming epidemics). In fact, the resounding success of artemisin has encouraged the development of
pharmaceutical derivatives of it and pyronaridin. See Bernard P~coul et. al, Access to Essential Drugs in
Poor Countries: A Lost Battle?, 281 JAMA 361, 367 (1999).
II See Kathy J. Kemper et al., Holistic Pediatrics: A Research Agenda, 103 PEDIATRICS 902-
09(1999).
112 See Kerry Hughes, Functional Foods: Back to the Future, PREPARED FOODS, Mar. 1, 2001,
at 35.
113 See id. Despite these anthropological findings, many western scientists remain skeptical.
According to one study, the mere presence of "shamans" in Laos and throughout Southeast Asia may
partly explain such skepticism, in that western scientists tend to dimly regard those who practice
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Furthermore, even when supplements lack measurable efficacy, they may
nevertheless help persons cope with illness, particularly when compared to more
stigmatizing modes of modem medical delivery."14  For instance, the steroid
dehydroepiandrosterone (a.k.a. "DHEA") has been identified as improving mental
well-being and reducing stress."l5  Many consumers prefer its over the counter
availability to stigmatizing or even embarrassing requests for prescription mental
health medicines.'" 6 Such subjective value comports with the modern description of
"holistic medicine": care of the whole patient (body, mind, relationships, emotions,
and spirit) in the context of the patient's values, culture, and community."l I
Accordingly, medical care based entirely on statistical, biological, or genetic factors
is unlikely to fully engage patients who have limited medical experience or technical
prowess and whose explanatory models often encompass cosmic, karmic, or spiritual
considerations. 118 By contrast, dietary supplement consumption, like interaction in
support groups and therapy, may yield methodologically-elusive, yet consistently
discernable, therapeutic benefit.
Subjective value associated with dietary supplements may be compared to that
of placebos. Indeed, physicians regularly employ placebos because they may induce
psychological or physiologic therapeutic effects that "effective" medicine cannot. 1 9
Moreover, placebos have been found not only to improve a patient's emotional well-
being,120 but also to catalyze physical healing.121
On the other hand, the concept of distrust appears salient for both supplements
and placebos. Indeed, one might negatively regard a dietary supplement company
which knowingly markets inefficacious products in the same way one might regard a
physician who "lies" to her patients by using placebos. Alternatively, from a
consumer autonomy perspective, neither a patient who unknowingly purchases a
medicine without formal education or training. See Laura Uba, Cultural Barriers to Health Care for
Southeast Asian Refugees, 107 PUB. HEALTH REP. 544, 548 (1992).
114 See Sanghavi, supra note 18. For instance, mental hospitalization is often regarded as highly
stigmatizing, and certain supplements may diminish the need for such hospitalization. See Daniel Luchins,
Refusing Care: Forced Treatment and the Rights of the Mentally Ill, 290 JAMA 674, 675 (2003).
Physicians can also be stigmatized by contemporary modes and norms of medical delivery. See e.g., Tracy
Hampton, Physicians Advised on How to Offer Pain Relief While Preventing Opioid Abuse, 292 JAMA
1164, 1162 (2004) (finding that physicians who prescribe pain medications often feel stigmatized within the
health care community).
"5 See Marilynn Larkin, DHEA: Will Science Confirm the Headlines?, 352 LANCET 208
(1998); see also Arline Kaplan, DHEA Lessens Depressive Symptoms, NIMH Study Shows, GERIATRIC
TIMES, Nov. 1, 2004, at 4 (describing soon-to-be released study finding that that DHEA may prove
more efficacious in treating mild-to-moderate midlife crisis than traditional antidepressant
treatments).
116 Id. See also Luchins, supra note 114, at 675 (describing stigma of pursuing mental health
medicines).
117 See Kemper et al., supra note 11; see also G. Yahn, The Impact of Holistic Medicine,
Medical Groups, and Health Concepts, 242 JAMA 2202, 2205 (1979) (offering historical survey of
holistic medicine and its systemic interaction with modem clinical expectations).
Hs See Delbanco T. Leeches, Spiders and Astrology: Predilections and Predictions, 280
JAMA 1560-62 (1998).
119 See Kathleen M. Boozang, The Therapeutic Placebo: The Case for Patient Deception, 54
FLA. L. REV. 687, 698-99 (2002); see also Barry Krakow et al., Placebo Effect in Posttraumatic Stress
Disorders, 284 JAMA 563 (2000) (identifying short-term value of placebos in treating posttraumatic
stress disorders).
120 See HOWARD BRODY, PLACEBOS AND THE PHILOSOPHY OF MEDICINE 16 (1980).
Intriguingly, these and similar phenomena have been evident since the practice of ancient priests
thousands of years ago. See ARTHUR K. SHAPIRO & ELAINE SHAPIRO, THE POWERFUL PLACEBO:
FROM ANCIENT PRIEST TO MODERN PHYSICIAN (1997).
121 Id. at 9.
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placebo nor a consumer who unknowingly purchases an ineffectual supplement
intends to purchase those items. These varying viewpoints underscore concern that
certain supplement companies deceive consumers, thus diminishing their products'
perceived therapeutic effect-much like concern that by undermining patient
confidence in the physician, placebos may diminish their perceived effect.
22
III. DIETARY SUPPLEMENT LAWMAKING & CONSUMER NORMS
Identifying normative consumer interaction with dietary supplements invariably
links to legal treatment of those supplements. Indeed, in a free market, lawmakers
ultimately choose the extent to which governmental regulation should steer products
and industries, and the extent to which consumers may choose risk. Common
considerations include requisite thresholds of product safety and effectiveness, as
well as desirable levels of governmental supervision. 123  Less nobly, other
considerations might include lobbying interests and political fundraising
implications. 1
24
In the last century, legislative treatment of dietary supplements has evoked
myriad considerations, often mixing economic constraints, social theory, and
political pretext. This Part will explore the evolution of American dietary
supplement law and how contrasting interests among the FDA, Congress, the dietary
supplement industry, and supplement users have influenced promulgation of laws
affecting dietary supplement consumption. This exploration may also illuminate
potentially beneficial changes in both regulatory authority and industry behavior,
particularly regarding consumer recognition of risk and benefit.
A. THE EARLY YEARS: MINIMAL DIETARY SUPPLEMENT REGULATION
Until the mid-19th century, dietary supplements, like most food and drugs, were
largely unregulated. 125 To the extent consumers received legal protection, it was
primarily based on state common law, with typical claims involving heavily-
marketed though highly-ineffective products, such as those basing their efficacy on
"secret formulas.' ' 126 Despite vast fraudulence, 19th century state tort laws scantly
recognized product liability, thus making cognizable claims difficult to establish.'27
Further burdening plaintiffs, courts would often legitimize "secret formulas" as
genuine ingredients.' 28 This was particularly evident among herbal products.
129
122 See Boozang, supra note 119, at 743.
123 See 109 CONG. REC. E316 (daily ed. Mar. 1, 2005) (statement of Rep. Moran); H.R. Res.
135, 109th Cong. (2005).
124 See generally 109 CONG. REC. H2534 (daily ed. Apr. 26, 2005) (statement of Rep.
Emanuel).
125 For an extensive historical review of food and drug law, see generally Peter B. Hutt & Peter
B. Hutt II, A History of Government Regulation of Adulteration and Misbranding of Food, 39 FOOD
DRUG COSM. L.J. 2 (1984). See also PETER BARTON HUTT & RICHARD A. MERRILL, FOOD AND DRUG
LAW: CASES & MATERIALS 6-10 (1991).
126 See Howard A. Denemark, Improving Litigation Against Drug Manufacturers for Failure to
Warn Against Possible Side Effects: Keeping Dubious Lawsuits from Driving Good Drugs Off the
Market, 40 CASE W. RES. L. REV. 413, 415-16 (1990); see generally STEWART H. HOLBROOK, THE
GOLDEN AGE OF QUACKERY 14-28 (1959) (providing extensive information on some of the most
outrageous products, many of which were heavily marketed).
127 Id. at 416.
128 Id. (discussing how "quacks" were undeterred by legal institutions and the law).
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Along these lines, distinction between "drug" and "dietary supplement" products
appeared fleeting. For instance, in Bailey v. Moog,130 a New York court heard the
claim of a physician whose prescriptive practice in 1847 comprised solely of roots,
barks and herbs.'
3 1
In 1850, however, the Massachusetts Sanitary Commission released an
influential report connecting toxic sewage and contaminated food and drug products
to declining mortality rates. 32 Following the report, states began to enact more
stringent health laws, including those which prohibited adulterated food.
133
However, many of these laws reflected disparate policies and lacked uniform
construction, thus resulting in substantial consumer confusion. 1
34
During this time period, federal powers to regulate food and drugs proved
especially restrained. Despite the lobbying efforts of reform movements-including
those initiated by merchants themselves13 5-as well as the late-19th century crusade
of Dr. Harvey Washington Wiley, Chief Chemist for the U.S Department of
Agriculture and legendary consumer advocate,' 36 the Supreme Court's interpretation
of the scope of the commerce clause constrained efforts to enact stringent food and
drug law.' 37 The essence of such interpretation significantly limited the scope of
federal commerce law to transactions which physically crossed state borders; at the
time, many food and drug transactions comprised intrastate activity. 3 8 On the other
hand, the federal government could attempt to regulate food and drugs through the
Postmaster General's authority to withhold delivery of fraudulent mail, but this
authority often proved inadequate. 139
In 1906, however, Congress reconsidered federal food and drug legislation,
particularly in light of increasing attention on "quackery."' 140 Publication of Upton
129 See, e.g., In re Eisner, 1893 U.S. App. LEXIS 2502 (C.C.S.D.N.Y. 1893) (noting that "[t]he
Johann Hoff Malt Extract is a compound of many ingredients, made by a secret formula, consisting of
herbs, roots, leaves, dextrine, water, hop extract and malt extract").
130 1847 N.Y. LEXIS 54 (N.Y. 1847).
131 Id. at *3; see also In re Hunter, 60 N.C. 447 (1864) (court distinguishing "physical herb"
from "medical herb").
32 See STEPHEN B. THACKER, HISTORICAL DEVELOPMENT IN PRINCIPLES AND PRACTICE OF
PUBLIC HEALTH SURVEILLANCE 3, 4 (Steven M. Teutsch & R. Elliot Churchill eds., 1994).
133 For instance, Dr. E.R. Squib, a merchant, spoke publicly about rampant fraud in the food
and drug industry, and the need to separate legitimate merchants from illegitimate ones. Other reform
parties included the American Medical Association, the American Public Health Association, labor
unions, and consumer groups. See Richard A. Merrill & Jeffrey K. Francer, Organizing Federal Food
Safety Regulation, 31 SETON HALL L. REV. 61, 79 (2000).
134 See Peter Barton Hutt, Lecture at Harvard Law School, Jan. 4, 2005 (comments on file with
author).
135 See HUTT& MERRILL, supra note 125, at 7-9.
136 Dr. Washington waged an uphill battle against fraudulent drugs and adulterated foods. To
prove his beliefs, he even assembled a "poison squad," a group of assistants who would test
contaminated food and drug products and then publicize the conclusions. See HARRY E. NEAL, THE
PROTECTOR'S: THE STORY OF THE FOOD AND DRUG ADMINISTRATION 12 (1970).
137 See Richard A. Epstein, Our New Federalism? National Authority and Local Autonomy in
the War on Terror, 69 BROOKLYN L. REV. 1421 (2004).
138 See id.
139 See, e.g., American School of Magnetic Healing v. McAnnulty, 187 U.S. 94, 109-10 (1902)
(finding that even when determining the fraudulence of a product, the Postmaster General lacked the
ability to make conclusions of law); Peter Barton Hutt, A History of Government Regulation of
Adulteration and Misbranding of Medical Devices, 44 FOOD DRUG COSM. L.J. 99, 101-02 (1989)
(noting how the FDA regularly collaborated with the Post Office in policing fraudulent food and drug
practices).
140 See Scott Bass & Alan Raul, The Single Food Safety Agency: A Modest Dialectic Dialogue,
59 FOOD DRUG L.J. 453, 455 (2004).
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Sinclair's The Jungle,'4 1 which dramatically illustrated the abundance of
contaminants in the food supply, only propelled legislative interest. 142  With
sufficient momentum, Congress passed and President Theodore Roosevelt signed the
Pure Food and Drugs Act of 1906 ("1906 Act").
143
Upon initial observation, the 1906 Act reflected "progressive legislation," since,
for the first time, the shipment of adulterated food and drugs was prohibited in
interstate commerce.144 The 1906 Act also empowered the FDA to pursue seizures
and other enforcement mechanisms against non-compliant food and drug
companies.
4 5
Nevertheless, the 1906 Act placated private industry by requiring the federal
government to discover dangerous food ingredients after a product entered the
market. 146 In contrast to pre-market approval or mandatory disclosure from private
industry, this approach offered limited certainty for consumers, particularly given
minimal enforcement resources. 147  Similarly restraining, though the 1906 Act
prohibited "dangerous" food ingredients, it largely preserved companies' capacity to
promote misleading claims. 148  Though Congress would pass the Shirley
Amendment149 to the 1906 Act in 1912, it too would prove restrictive, since
sustaining a charge that labeling was "false and fraudulent" obligated the
government to prove not only that the claims were untrue, but that the seller knew
they were untrue.' 50 Perhaps most significantly, the 1906 Act declined to impose
nutritional or ingredient labeling requirements, aside from the disclosure of narcotic
drugs and net weight.'
51
By using the state police power, however, several states imposed greater
disclosure requirements on food labels, a trend supported by some courts. For
instance, in 1906, Indiana passed a law requiring the disclosure of ingredients in
animal food. In Savage v. Jones,152 the U.S. Supreme Court held that the act did not
violate the Commerce Clause, merely reflected a valid exercise of the state police
power, and was not preempted by the 1906 Act. 53 This holding proved notable,
particularly in light of the Court's 1905 holding in Lochner v. New York, 154 which
141 UPTON SINCLAIR, THE JUNGLE (1906).
142 See Merrill & Francer, supra note 133, at 79.
143 Pub. L. No. 59-384, § 2, 34 Stat. 768 (1906).
144 See Hipolite Egg Co. v. United States, 220 U.S. 45, 54 (1911) (holding that the purpose of
the 1906 Act was to keep misbranded and adulterated products "out of the channels of interstate
commerce, or, if they enter such commerce, to condemn them while being transported or when they
have reached their destinations, provided they remain unloaded, unsold or in original unbroken
packages").
145 See HUTT & MERRILL, supra note 125, at 8-9.
146 Pure Food and Drugs Act of 1906 § 2.
147 Id.; see generally MARION NESTLE, FOOD POLITICS: HOW THE FOOD INDUSTRY
INFLUENCES NUTRITION AND HEALTH (2002) (noting historical lack of resources for FDA). For an
expanded discussion of the Pure Food and Drugs Act, see Lars Noah & Richard A. Merrill, Starting
from Scratch?: Reinventing the FoodAdditive Approval Process, 78 B.U. L. REV. 329, 331 (1998).
148 See United States v. Johnson, 221 U.S. 488, 497-98 (1911) (Justice Holmes holding that a
false claim to cure cancer did not satisfy the requirement that the claim be dangerous). But see Laufer
T. Hayes & Frank J. Ruff, The Administration of the Federal Food and Drugs Act, I LAW &
CONTEMP. PROBS. 16 (1933) (noting that the 1906 Act prohibited false claims).
149 Pub. L. No. 62-301, 37 Stat. 416 (1912).
]so See Merrill, supra note 31, at 1760-61.
151 See generally Hayes & Ruff, supra note 148.
152 225 U.S. 501 (1912).
153 Id. at 531 (holding that "Congress has thus limited the scope of its prohibitions. It has not
included that at which the Indiana statute aims").
154 198 U.S. 45 (1905).
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established a thirty-year judicial skepticism towards most public interest
legislation.'
55
B. THE FDCA & FOOD ADDITIVES AMENDMENT: MODERATE DIETARY
SUPPLEMENT REGULATION
Despite the presence of more stringent state labeling laws, the need for
enhanced federal food and drug legislation became apparent in 1938, when seventy-
three people died from ingesting Elixir Sulfanilamide, which had not been tested
prior to its introduction on the market. 156 Later that year, Congress replaced the
1906 Act with the FDCA,157 which enlarged FDA authority to regulate food and
drugs. The FDCA also established jurisdictional boundaries between the FDA and
the Federal Trade Commission, with the FDA and FTC receiving primary
jurisdiction for labeling and advertising, respectively. 158
Notably, for the first time, Congress described dietary supplements as a category
of food for "special dietary purposes"' 59 and, under Section 4030), authorized the
FDA to promulgate regulations pertaining to those purposes.160 Specifically, Section
4030) required that manufacturers label supplements with content information,
including the amount of vitamins, minerals, and other properties. 161 Foods offered
for "special" dietary uses, therefore, warranted greater regulatory attention than
regular foods.
The FDCA contained certain limitations, however. Specifically, it both
preserved the absence of premarket approval and imposed minimal disclosure
requirements. 162 As a result, dietary supplements could continue to enter the market
without significant safeguards. Moreover, in light of the FDCA's bounded counters,
the FDA initially promulgated dietary supplement regulations of mixed effect.
163
Consider the agency's first such set of regulations in 1941.164 At first glance, they
appeared compelling, as they stipulated minimal daily requirements and labeling
guidelines for vitamins and minerals. 165 They also further refined the definition of
"special dietary uses," including uses which "exist by reason of a physical,
physiological, pathological or other condition."' 66 On the other hand, because the
FDCA only empowered regulation of supplement labeling, the FDA could not
155 See Nickolai G. Levin, Constitutional Statutory Synthesis, 54 ALA. L. REV. 1281, 1328-29
(2003).
156 See David F. Cavers, The Food, Drug, and Cosmetic Act of 1938: Its Legislative History
and Its Substantive Provisions, 6 LAW & CONTEMP. PROBS. 2, 20 (1939). Also significant was the
1917 Report of the USDA Bureau of Chemistry, which advocated greater FDA enforcement powers.
See HUTT & MERRILL, supra note 125, at 10-11.
157 Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended at 21 U.S.C. §§ 321-393
(2000))
158 See HUTT & MERRILL, supra note 125, at 187.
159 Gardner v. Toilet Goods Ass'n, 387 U.S. 167, 180 (1967) (citing 21 U.S.C. § 3430)).
160 21 U.S.C. § 4030) (2000).
161 See id. (including under the definition of misbranded food any item which "purports to be
or is represented for special dietary uses, unless its label bears such information concerning its
vitamin, mineral, and other dietary properties as the Secretary determines to be, and by regulations
prescribes as, necessary in order to fully inform purchasers as to its value for such uses").
162 For a discussion, see Noah & Merrill, supra note 147, at 331-34.
163 See Meghan Colloton, Dietary Supplements: A Challenging Facing the FDA in Mad Cow
Disease Prevention, 51 AM. U. L. REV. 495, 512 (2003).
164 21 C.F.R. § 125 (1941).
165 21 C.F.R. § 125.
166 6 Fed. Reg. 5921 (1941).
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address the safety and efficacy of the supplements themselves.' 67 Rather, the FDA
merely required a label disclaimer that the values of supplements "in human
nutrition have not been established."' 168 Perhaps not surprisingly, these regulations
encountered minimal resistance from the courts, the dietary supplement industry,
and consumers.
169
Nevertheless, food safety improved significantly around this time, as food
companies more regularly tested their ingredients. 70  Such enhanced voluntary
behavior partly reflected the burgeoning viability of private tort liability,' 7' as well
as the mere threat of adverse publicity, which became more prevalent with the rise
of radio and television media. 172 Moreover, though the FDA's continued burden of
discovering dangerous ingredients hampered regulatory enforcement, the agency
appeared uniquely resilient in ensuring accurate supplement labeling.'73 This
resilience was best evidenced by the Nutrilite Consent Decree,174 which, through a
series of litigations, resulted in new guidelines for dietary supplement companies
that discouraged false claims. 175  The FDA also benefited from a fairly liberal
judicial interpretation of "labeling" under the FDCA. Specifically, in Kordel v.
United States,176 the U.S. Supreme Court held that pamphlets and other
advertisements mailed separately from products and their attached labels are
included within the statutory definition of "labeling."'
177
Subsequent legislative initiatives only buttressed the FDA. Namely, by passing
the Food Additives Amendment to the FDCA171 in 1958, Congress established a pre-
market approval system for food ingredients. Legislative desire to do so derived
from concern over the growing use of chemicals in foods. 17 9 Through the Food
167 See Kaczka, supra note 80, at 468; see also Michael F. Markel, Foods for Special Dietary
Uses-An Historical Outline of Regulatory Aspects, 22 FOOD DRUG COSM. L.J. 110, 114 (1967).
168 See, e.g., 6 Fed. Reg. 5921, 5925 (Nov. 22, 1941); 6 Fed. Reg. 3304, 3310 (July 8, 1941); 5
Fed. Reg. 3565 (Sept. 5, 1940); see also Margaret Gilhooley, Herbal Remedies and Dietary
Supplements: The Boundaries of Drug Claims and Freedom of Choice, 49 FLA. L. REV. 665, 672
(1997) (describing the limitations of such regulatory language).
169 See I. SCOTT BASS & ANTHONY L. YOUNG, DIETARY SUPPLEMENT HEALTH AND
EDUCATION ACT: A LEGISLATIVE HISTORY AND ANALYSIS 9 (1996).
17o See Noah & Merrill, supra note 147, at 336 (citing Food Additives: Hearings Before a
Subcomm. of the House Comm. on Interstate and Foreign Commerce, 85th Cong. 421-22 (1957)
(statement of Elliot L. Richardson, Asst. Secretary, Health, Education & Welfare (HEW) ("The
commendable actions of the great majority [of companies], however, cannot provide protection
against the minority. We have had some narrow escapes in the food field."))).
171 See Robert C. Brown, The Liability of Retail Dealers for Defective Food Products, 23
MINN. L. REV. 585, 596-610 (1939).
172 See Noah & Merrill, supra note 147, at 336.
173 See Peter Barton Hutt, Government Regulation of Health Claims in Food Labeling and
Advertising, 41 FOOD DRUG COSM. L.J. 3 (1986).
174 United States v. Mytinger and Casselberry, Inc. FDA Not. of Jud. No. 3383 (S.D. Cal.
1951), reprinted in FEDERAL FOOD DRUG AND COSMETIC ACT 1951-1952, at 204 (FDLI
1953).
175 See Hutt, supra note 173, at 52; see also Lester L. Lev, The Nutrilite Consent Decree, 7
FOOD DRUG COSM. L.J. 56, 56 (1952); Kaczka, supra note 80, at 471 (contending that the FDA
successfully pursued implementing the Nutrilite Consent Decree); Mark A. Kassel, From A History of
Near Misses: The Future of Dietary Supplement Regulation, 49 FOOD & DRUG L.J. 237 (1994)
(finding that while the FDA generally failed to use litigation to ensure safety of food products, the
agency perceived greater success with dietary supplements, particularly through the NCD).
176 335 U.S. 345 (1948)
177 Id. at 349-50.
178 Food Additives Amendment of 1958, Pub. L. No. 85-929, 72 Stat. 1784 (codified as
amended in scattered sections of 21 U.S.C. (2000)).
179 See Noah & Merrill, supra note 147, at 336-40.
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Additives Amendment, Congress shifted the burden of proving food safety from the
FDA to individual manufacturers, as it mandated that food additives-but not food
ingredients-could be used only with prior FDA approval. 180 Equally important, the
Food Additives Amendment included dietary ingredients in the definition of a food
additive, thus imposing the more stringent treatment if those ingredients were not
GRAS.' 8'
C. 1960s -1980s: PRODUCT PROLIFERATION & INTEREST GROUP MANIPULATION
Despite enhanced oversight powers, the FDA struggled to regulate dietary
supplements, particularly as they proliferated in the early 1960s. 8 2 Indeed, though
the FDA brought hundreds of court actions against misleading supplement claims in
the 1960s, case-by-base enforcement proved of limited effectiveness.' 83 This was
especially true of herbs, which often blurred the line between medicine and food. 84
Since neither the FDCA nor its implementing regulation specified the requisite
dietary properties of herbs, the FDA possessed scant regulatory authority to combat
such "quackery.' ' 185 Illustrating the agency's frustration at that time, then FDA
Commissioner George P. Larrick characterized dietary supplements as "the most
widespread and expensive type of quackery in the United States."'' 86
In response to the proliferation of inefficacious dietary supplements, the FDA
attempted to revise its regulations in 1962, proposing clear potency levels on
vitamins and minerals, and requiring that supplements contain ingredients of
established nutritional quality.' 87  These proposed regulations underscored the
FDA's belief that dietary supplements should augment nutritional needs, 188 such as
presumed widespread nutritional deficiency among the population, rather than
mythical wants. 189 Of perhaps equal importance, the political climate for such
industry-averse regulations may have appeared hospitable. Indeed, Congress had
passed the Kefauver-Harris Amendment'90 in 1962, thereby establishing FDA pre-
market approval of drug efficacy claims.191
180 Id.
181 See Stephen H. McNamara, Dietary Supplements of Botanicals and Other Substances: A
New Era of Regulation, 50 FOOD & DRUG L.J. 341 (1995).
182 See generally HUTT & MERRILL, supra note 125.
183 See id. at 207 n.2; see also Gilhooley, supra note 168, at 673 (describing the ineffectiveness
of the case-by-case approach).
184 See Kaczka, supra note 80, at 471-72; see also William R. Pendergast, Dietary
Supplements, in I FUNDAMENTALS OF LAW AND REGULATION 266 (FDLI 1997).
185 See Kassel, supra note 175, at 262.
186 Sean Harmon, Melatonin Mania: Can the FDA Regulate Hormonal Dietary Supplements to
Protect Consumer Interests in Light of the Dietary Supplement Health and Education Act of 1994?, 22
DAYTON L. REV. 77, n. 2 (1996) (citing Ralph L. Smith, The Vitamin Healers, THE REPORTER, Dec.
16, 1965, at 18-25).187 See Dietary Foods, 31 Fed. Reg. 8521, 8522 (June 18, 1966).
188 27 Fed. Reg. 5815 (June 20, 1962).
189 See Gilhooley, supra note 168, at 673; see also William W. Goodrich, The Coming Struggle
over Vitamin-Mineral Pills, 20 BUs. LAW. 145 (1964) (describing how dietary supplement
manufacturers often asserted that daily food consumption failed to provide sufficient nutrients).
190 Pub. L. No. 87-781, 76 Stat. 780 (1962) (codified at 21 U.S.C. § 355 (2000)) (the
amendment is also commonly known as the "Drug Efficacy Amendment").
191 The requisite political support for the Kefauver-Harris Amendment was derived largely
from the thalidomide tragedy. The pre-market approval process of claims required controlled studies,
unless the product was generally recognized by experts as effective based on similar studies. See
generally Gilhooley, supra note 168, at 672.
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Despite agency momentum and conceivably opportune political timing, the
FDA encountered significant resistance to its proposed reforms. Of greatest
challenge, a significant percentage of supplement consumers believed in
unsubstantiated product assertions, and many campaigned against potency limits and
other restrictions on their preferred products. 192 These quixotic beliefs partly related
to unregulated supplement claims, which often revealed information in promotional
or misleading schemes.' 93  To the dismay of many consumers, the proposed
regulations would have severely curtailed the sale of multi-vitamin and mineral
products, as many of those products exceeded potency levels or utilized unreliable
ingredients. 94  As a result, an emboldened dietary supplement industry lobbied
Congress to dismiss the proposals and even to refrain from holding public
hearings. 195
Four years later, the FDA proposed a new line of dietary supplement
regulations, which continued to advance potency limits, but also proposed that
dietary supplement labels include the following stark warning: "there is no scientific
basis for recommending routine use of dietary supplements."' 96  The proposal
sparked a five-year battle between the FDA and the dietary supplement industry,
much of which transpired during acrimonious public hearings.' 
97
The White House Conference on Food, Nutrition, and Health in 1969 ("White
House Conference") also proved salient in the controversy. That year, President
Richard M. Nixon convened leaders in the food and drug industry to develop anti-
hunger strategies for poorer American communities, but the conference ultimately
produced a Conference Report condemning a restrictive approach to dietary
supplements and their labels. 198 The Report instead championed the ability of
emerging food technology to help consumers satisfy their nutritional needs, as well
as the potential for labeling to inform consumers rather than set rigid standards for
product composition.'
99
In response to the White House Conference and public hearings, the FDA
published final regulations in 1973 ("the 1973 regulations") that were set to take full
effect in 1975.200 These regulations resembled those proposed in 1966, but did not
include the warning label.20 ' Significantly, by establishing potency limits, the
regulations required that any vitamin or mineral with a dosage exceeding 150
percent of the recommended daily allowance be subjected to the more arduous drug
approval process.20 2 Of equal significance, the regulations stipulated that excessive
192 id. at 673.
193 See generally id.
194 See 27 Fed. Reg. 5815, 5815 (1962); Kaczka, supra note 80, at 472.
195 See Goodrich, supra note 189.
196 Dietary Foods, 31 Fed. Reg. 8521, 8525 (proposed June 18, 1966).
197 See Definition, Identity, and Label Statements; Proposed Findings of Fact, Conclusions,
and Tentative Order Following a Public Hearing, 38 Fed. Reg. 2152, 2153 (proposed Jan. 19, 1973)
(outlining hearings that led to 1973 proposed rule making). For an excellent review of the hearings,
see Colloton, supra note 163, at 515-16.
198 See Peter Barton Hutt, Regulating the Misbranding of Food, 43 FoOD TECH. 288 (1989);
see also Hutt, supra note 167 (describing significance of contemporaneous staff changes at the FDA).
199 Id.
200 See Dietary Supplements of Vitamins and Minerals, 38 Fed. Reg. 20730, 20731 (Aug. 2,
1973) (codified at 21 C.F.R. §§ 105.3, 105.60, 105.77, 105.85 (2005).
201 Id.
202 See 38 Fed. Reg. 20716 (1973).
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doses of certain ingredients would statutorily convert affected supplements into
drugs, unless the manufacturer demonstrated a nutritional need for the dose. °3
Despite omitting the warning label requirement, the 1973 proposal attracted
considerable criticism from the dietary supplement industry, particularly in regards
to its potency limits and its statutory conversion of certain supplements into drugs.20 4
Similarly influential, the problem of "hunger in America" became paramount in
media coverage and political rhetoric. 20 5  Such criticism immediately spawned
litigation. In National Nutritional Foods Association v. Food & Drug
Administration, 206 the U.S. Court of Appeals for the Second Circuit fielded legal
objections from fifteen parties-primarily vitamin and food supplement
manufacturers-concerning whether the FDA possessed the authority under the
FDCA to set qualitative and quantitative standards of identity for dietary
supplements containing vitamins and minerals. 207 The court offered a mixed result,
largely sustaining the potency limits20 8 but finding unreasonable the rules governing
supplements which exceeded the recommended daily allowances. 20 9  Similarly
mixed was the court's reasoning that a supplement could not be considered a drug
unless its manufacturer so "intended," and that intent could not be determined solely
by nutritional usefulness, as argued by the FDA, or by the manufacturers' claims, as
argued by the manufacturers, but rather by a nebulous middle ground.210
Many industry and consumer groups were dissatisfied with National Nutritional
Foods Association, as potency limits deterred research and development of high-
potency supplements, with manufacturers sufficiently dissuaded by the costs and
211delays commonly associated with the drug review process.. In response to intense
industry lobbying efforts, Congress passed the Vitamin-Mineral Amendment of
1976212 (more commonly known as the "Proxmire Amendments"), which amended
the FDCA by largely removing the teeth of FDA dietary supplement regulation.
Specifically, the Proxmire Amendments eliminated maximum limits on the potency
of supplements213 and on combinations of vitamins and minerals 214 and prohibited
the classification of any supplement as a drug based on presumptively excessive
potency.1 5
203 See 38 Fed. Reg. 20708, 20730 (1973).
204 In fact, there were nearly 22,000 responses to the proposed regulations. See Colloton,
supra note 163, at n.140 (citing 38 Fed. Reg. 20730). It is arguable that RDAs had originally been
devised as a measurement standard for scientific and governmental research purposes, not as an
enforceable standard for the general population. See MONICA MILLER, FOUNDATION FOR THE
ADVANCEMENT OF INNOVATIVE MEDICINE, The History of Dietary Supplement Regulation, available
at http://www.faim.org/supplements.htm (last accessed May 31, 2005).
205 See HUTT & MERRILL, supra note 125, at 215.
206 504 F.2d 761 (2d Cir. 1974).
207 ld. at 767.
208 Note that, even with potency limits, consumers could still digest the same level of
supplements by consuming a greater number of reduced-sized tablets. See National Nutritional
Foods, 504 F.2d at 792 (Judge Friendly suggesting that consumers could "take as many more tablets"
as needed to procure the desired effect).
209 Id. at 783-84.
210 Id. at 789; see Gilhooley, supra note 168, at 674 (explaining how "intent" was proscribed).
211 See BASS & YOUNG, supra note 169, at 12; see also Kassel, supra note 175, at 257
(detailing lobbying efforts).
212 Pub. L. No. 94-278, 90 Stat. 410 (1976) (codified as amended at 21 U.S.C. § 350 (2000)).
213 See 21 U.S.C. § 350(a)(1)(A) (2000).
214 See 21 U.S.C. § 350(a)(1)(C) (2000).
215 See 21 U.S.C. § 350(a)(l)(B) (2000).
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Taken together, National Nutritional Foods Association, the Proxmire
Amendments, and the increasingly accordant relationship between Congress and the
dietary supplement industry severely discouraged FDA efforts to regulate
supplements. In fact, by the early 1980s, the agency scaled back its regulatory
efforts 216 and, as a general matter, pursued enforcement action against dietary
supplement companies only when supplements made either express drug claims or
outrageous declarations. With such diminished deterrence, the number of
supplements on the market exploded. 21 8 The frequency with which these products
made health related claims on packaging also increased.21 9
By the end of the 1980s, however, greater public attention to the dangers of
unregulated dietary supplements arose, particularly since unfounded, confusing, and
misleading disease claims were omnipresent on most dietary supplement labels.
220
This was perhaps best evidenced by the amino acid dietary supplement L-trytophan,
to which the federal Centers for Disease Control attributed thirty-eight deaths in
1989. 22  Less troubling only in comparison, many dietary supplements promoted
222
audacious claims without even minimal scientific support.
D. NUTRITION LABELING AND EDUCATION ACT OF 1990: LABELING WARS BEGIN
Motivated partly by concern that consumers lacked sufficient nutritional
information for dietary supplements,2 2 3 Congress passed the Nutrition Labeling and
Education Act of 1990 ("NLEA") 224 to strengthen the FDA's legal authority to
require nutritional labeling on food.225  Specifically, the NLEA added two
subsections-(q) and (r)-to Section 403 of the FDCA, thereby creating two new
food-labeling provisions.226 Section 403(q) specifies the general nutritional labeling
standards and requirements, while section 403(r) prohibits food manufacturers from
making unsubstantiated disease prevention or nutrient description claims. 22' Though
the NLEA authorized health claims for foods, it required that such claims receive
premarket approval from the FDA 228 and be based on well-designed studies and
216 See Gilhooley, supra note 168, at 676; see also General Accounting Office, Report to
Senator Kennedy, at 4 (B252966, July 2, 1993), reprinted in BASS & YOUNG, supra note 169, at 300
(noting that the agency was "dissuaded" by the Proxmire Amendment) [hereinafter GAO Report].
217 See GAO Report, supra note 216, at 6.
218 Regulation of Dietary Supplements, 58 Fed. Reg. at 33,698-99 (June 18, 1993) (discussing
the market prevalence of dietary supplements).
219 See Howard M. Rubin, Courts, Congress Re-examine Nondrug Products, 21 NAT'L L.J.,
July 5, 1999, at B8.
220 See Nutritional Health Alliance v. Shalala, 953 F. Supp. 526, 526 (Dist. Ct. S.D.N.Y.
1997).
221 See Christopher Smith, Supplements and the Feds, SALT LAKE TRIB., May 21, 2001, at A8.
222 See David C. Vladeck, Truth and Consequences: The Perils of Half-Truths and
Unsubstantiated Health Claims for Dietary Supplements, 19 J. PUB. POL'Y & MARKETING 132 (2000).
For instance, dietary supplement companies marketed claims ranging from "Stone Free Kidney and
Gall Formula" to "Fat Burners," which erroneously suggested effective treatments for serious
afflictions. Id.
223 Id.
224 Pub. L. No. 101-535, 104 Stat. 2353 (1990) (codified as amended at 21 U.S.C. §§ 301-
397).
225 For an expanded discussion of the NLEA, see Michael A. McCann, Economic Efficiency
and Consumer Choice Theory in Nutritional Labeling, 2004 Wis. L. REV. 1161, 1187-91 (2004).
226 § 2, 104 Stat. at 2353-57 (codified as amended at 21 U.S.C. § 343).
227 See McCann, supra note 225, at 1187 (discussing § 2, 104 Stat. at 2353-59).
228 See § 3, 104 Stat. at 2358.
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significant scientific agreement. 9 Following passage of the NLEA in 1990, the
FDA issued revised nutrition labeling regulations for food products to update the
1973 regulations, which had required disclosure of any vitamin, mineral, or
nutrient. 230 In general, the revised regulations require scientific agreement among
qualified experts about the safety of ingredients in food products. 23'
The subject of dietary supplements received considerable attention in
promulgating NLEA. 232  Intriguingly, despite the long-standing feud between
Congress and the FDA over dietary supplements, Congress declined to prescribe a
substantive standard for dietary supplements in the NLEA. Rather, by instructing
the FDA to propose dietary supplement regulations by 1991, Congress invited FDA
233
clarity on dietary supplements. Like always, however, politics were not
unimportant in Congress' willingness to delegate: It was thought that newly-
appointed FDA Commissioner David Kessler, a former aide to Senator Orrin Hatch,
would promote moderate and restrained regulatory impositions on the dietary
supplement industry.234
Doubtless to the surprise of many, Dr. Kessler announced extensive plans for
the FDA to "restore credibility and integrity" in the dietary supplement market.
235
For instance, he proposed to ban many dietary ingredients as unapproved food
additives.236 The hallmark of those plans, however, included consonant health claim
standards for food and dietary supplement labels, with each requiring established
scientific grounding and pre-market FDA approval. 7 Significantly, at that time, the
FDA interpreted such standards to mean that no dietary supplements were qualified
to furnish health claims on their product labels. 238 The regulations were set to take
effect in November 1992, with a subsequent seven-month grace period for
compliance.
Predictably, the proposed regulation rippled through the halls of Congress, as
well as the offices of dietary supplement lobbying firms and public interest groups.
On one hand, consumer groups praised the FDA, surmising that consumers of
supplements should be accorded the same protection as consumers of food products.
Likewise, the National Association of Attorney Generals swiftly passed a resolution
229 Id; 21 U.S.C. § 343(r)(3)(B)(i).
230 21 C.F.R. § 101.9(a)(l) (2004).
231 Until 1997, health claims required FDA premarket approval, which was based on "the
totality of publicly available scientific evidence . . . [that the claim is supported by] significant
scientific agreement, among experts qualified by scientific training and experience." 21 U.S.C. §
343(r)(3)(B)(i). In 1997, the Food and Drug Administration Act was passed, which largely removed
the requirement of FDA approval, but still mandated that claims for non-restauarant food be derived
from "authoritative statements" of a scientific body. See McCann, supra note 225, at 1189.
232 See Gilhooley, supra note 168, at 679.
233 See 21 U.S.C. § 343(r)(5)(D) (2000) ("A subparagraph (1)(B) claim made with respect to a
dietary supplement of vitamins, minerals, herbs, or other similar nutritional substances shall not be
subject to subparagraph (3) but shall be subject to a procedure and standard, respecting the validity of
such claim, established by regulation of the Secretary").
234 See Smith, supra note 186.
235 Senator Hatch would later say that his former aide, Dr. Kessler "had been captured" by the
FDA. Id.
236 See Hearing Before the Subcomm. On Health and Environment of the House Comm. on
Energy and Commerce, 108th Cong. (2003) (remarks of David Kessler).
237 See NPR: Dietary Supplements and Regulations Pertaining to Them, (NPR radio broadcast,
Apr. 19, 1999) (noting remarks from Dr. David Kessler, former head of the FDA) [hereinafter NPR
Transcript].
238 See Gilhooley, supra note 168, at 679.
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affirming the FDA's position, reasoning that such regulations would advance state
health policies.239
On other hand, even the FDA recognized that its proposed regulations would
upset the dietary supplement industry, holistic groups, and numerous elected
officials. Indeed, consider language employed by the FDA to preface its proposed
regulation: "The Agency recognizes that proposing the same standard for
conventional food and dietary supplements is contrary to the view expressed by
some members of Congress.. Almost immediately, holistic groups, which
regarded higher standards as mere concessions to the pharmaceutical industry, and
the supplement industry, which resented an arguably zealous FDA, pressured
Congress to preempt implementation of the proposed FDA regulations with new
legislation. 241 Their positions were not entirely unfounded, as the Surgeon General
and National Research Council had recently issued studies discouraging the
treatment of dietary supplements as food products.242
Before the FDA regulations were implemented in November 1992, Congress
passed the Dietary Supplement Act of 1992243 ("1992 Act"), which imposed a one-
year delay on regulatory implementation. 244  Moreover, to promote distinction
between food products and dietary supplements, the 1992 Act mandated that the
FDA propose specific (and therefore different) rules for dietary supplements. 245 By
delaying regulatory implementation and by mandating a new set of proposed FDA
regulations, the 1992 Act also served a tactical purpose: provide Congress more time
to pass industry-friendly legislation.
In 1993, however, the FDA issued a controversial "Advance Notice of Proposed
Rulemaking" ("Advanced Notice") that only further riled FDA critics in Congress,
particularly those with close ties to herbal supplement manufacturers.
246
Unabashedly, the FDA concluded that "many herbs have no known history of food
use and, even without drug claims, are used for medical purposes. Many of these
herbs have a history of use as traditional medicines in many countries outside of the
United States. 247  The FDA also found a significant pattern of adverse effects
associated with various herbal dietary supplements, 248 thus motivating a renewed
agency desire to curtail sale of hazardous herbal products.24 9 Moreover, less than
one year later, a resolute, if perhaps dogmatic, FDA responded to the 1992 Act by
proposing a strikingly familiar regulatory scheme: that dietary supplements and food
products share the same regulatory treatment for health claims.
250
239 See National Association of Attorneys General Summer Meeting, Resolution on Deceptive
Claims in Dietary Supplement Labeling and Advertising, 49 FOOD & DRUG REPORT 474 (1993).
240 See MILLER, supra note 204.
241 See NPR Transcript, supra note 237.
242 See William J. Kolasky, Jr., The Impact of the Food and Drug Administration's Reproposal
on Vitamins, Minerals, and other Nutritional Supplements, 45 FOOD DRUG COSM. L.J. 639, 644-45
(1990).
243 Dietary Supplement Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491 (1992).
244 Id. at § 202(a)(1).
245 Id. at § 202(a)(2)(A).
246 See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690 (June 18, 1993).
247 Id. at 33,697.
248 Id. at 33,698 (for example, the FDA noted that toxic hepatitis has been associated with the
consumption of chaparral, a popular herbal supplement).
249 Id.
250 Food Labeling: General Requirements for Health Claims in Dietary Supplements, 58 Fed.
Reg. 33,700, 33,700 (June 18, 1993).
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E. CONFIGURING DIETARY SUPPLEMENTS AS FOOD ADDITIVES: THE WAR
CONTINUES
The FDA's characterization of certain dietary ingredients as food additives only
further provoked the dietary supplement industry, as such characterization imposed
more costly approval requirements under the FDCA . Indeed, consider the burden-
shifting between a food additive, a presumptively unsafe product for which the
processor bears the burden of demonstrating safety, and a GRAS dietary ingredient,
a presumptively safe product for which the FDA bears the burden of proving it
injurious to health 2  More specifically, by requiring that supplement manufacturers
meet the food additive standard, the FDA compelled documentation that the
scientific community considered the supplement safe.253 The cost of obtaining such
documentation typically proved exorbitant, often entailing extensive research, 15 or
years or more of data accumulation, and the wherewithal to absorb repeated and
meaningful expenses inherent in FDA administrative proceedings.25 4 It is estimated
that such costs would exceed $1,000,000 per product, with many products ultimately
failing to receive approval. 5
Perhaps best illustrating this zeal, consider the FDA's attempted regulation of
black currant oil ("BCO"), an extract from the seeds of the black currant berry and
marketed as a dietary supplement because of its fatty-acid structure.256 The FDA
contended that BCO was not GRAS and became a food additive when combined
with the gelatin and glycerin used to form capsules.257 As a result, BCO capsules
could not be marketed as dietary supplements without satisfying the more arduous
food additive approval process. 8 The FDA held this position even though gelatin
and glycerin were used as preservatives, and even though BCO was not considered a
food additive when vended in bottled liquid form.
25 9
To the FDA's dismay, however, two U.S. Courts of Appeal disagreed with
agency, finding that BCO comprised the sole dietary ingredient of BCO capsules and
thus should have been considered a food itself rather than a food additive. Indeed,
the courts deemed the capsules mere delivery mechanisms for BCO ingestion.
260
Most alarming to the courts were the "common sense" implications of the FDA's
position: "The proposition that placing a single-ingredient food product into an inert
capsule as a convenient method of ingestion converts that food into a food additive
251 See Phil Wallace, Senate Increases Funding for Labeling Enforcement, FOOD CHEMICAL
NEWS, Nov. 12, 2001, at 21. Senator Tom Harkin (D-IA) said of the FDA, "We admonish the agency
not to wield the heavy hand it did for over three decades, the over-bearing attitude which led Congress
to pass [DSHEA] so overwhelmingly in the first place." Id.
252 See United States v. An Article of Food, 678 F.2d 735, 739 (7th Cir. 1982).
253 See Regulation of Dietary Supplements, 58 Fed. Reg. at 33,692 n.2.
254 See FDA Safeguards Against Improper Disclosure of Financially Sensitive Information:
The Product Approval Centers, Final Report 162 (Nov. 14, 1991) reprinted in 33 FOOD CHEM. NEWS,
Nov. 4, 1991, at 67.
255 See McNamara, supra note 181, at 343.
256 See United States v. Two Plastic Drums, 984 F.2d 814 (7th Cir. 1993).
257 See id. at 816. The FDA's reasoning behind this structural argument rested in 21 U.S.C. §
321(s), with the agency surmising that the BCO became a literal "component" of food when combined
with two other "components." Id.
258 See Stephen H. McNamara & A. Wes Siegner, FDA has Substantial and Sufficient
Authority to Regulate Dietary Supplements, 57 FOOD DRUG L.J. 15, 16 (2002); see also S. REP. NO.
103-410, at 16 (Oct. 8, 1994) ("The cost to a manufacturer to prepare a food additive petition can run
to $2 million. FDA approval of a food additive petition typically takes from 2 to 6 years.").
259 S. REP. NO. 103-410, at 16 (OCT. 8, 1994)
260 See United States v. 29 Cartons, 987 F.2d 33, 37-39 (Ist Cir. 1993); Two Plastic Drums,
984 F.2d at 820; see also Noah & Merrill, supra note 147, at 346-47.
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perverts the statutory text, undermines legislative intent, and defenestrates common
sense."2 6' In fact, as commentators have noted, if the FDA's expansive
interpretation of food additives had been deemed valid, other food products,
including dietary supplements, might also have been considered food additives, thus
262
shifting the burden of proving safety onto their processors.
The FDA's desire to treat dietary supplements as food additives clearly
threatened to impose greater production costs on dietary supplement makers and
limit their capacity to promote unrealistic claims.263 Whether such stem treatment
reflected excessive bureaucratic caution or appropriate protection remains a source
of scholarly debate.264 Of greater certainty and perhaps symbolism, such treatment
reflected a growing chasm between the FDA, Congress, and dietary supplement
companies, and one that also appeared increasingly irreparable.265
F. DIETARY SUPPLEMENT HEATH & EDUCATION ACT: INDUSTRY WINS WAR
By the fall of 1994, the widening philosophical gulf between Congress and the
FDA resulted in a legislative enactment crafted largely to the favor the dietary
supplement industry: DSHEA.266  Though the proposal encountered initial
opposition, 26 7 it soon muted as the Nutritional Health Alliance, an industry group
with close ties to both Democratic and Republican members of Congress, persuaded
even the fiercest of Democratic critics to "speak softly. ' 2 68 As a result, sufficient
bipartisan support emerged, and, steered by the adroit stewardship of Senator Hatch,
DSHEA quickly advanced through the legislative process, 26 9 acquiring Senate
approval on a voice vote with only a few senators present. 270 Ostensibly, DSHEA
sought to "supersede the [existing] ad hoc patchwork regulatory policy on dietary
supplement" with one that removed "unreasonable regulatory barriers limiting or
slowing the flow of safe products and accurate information to consumers." 271 By
accomplishing more barrier removal than informational flow, DSHEA yielded
significant latitude to dietary supplement companies in manufacturing and
promoting their products, arguably at the expense of consumer safety.
261 29 Cartons, 987 F.2d at 39.
262 See Noah & Merrill, supra note 147, at 347.
263 Id. at 349.
264 See, e.g., Elizabeth C. Price, Teaching the Elephant to Dance: Privatizing the FDA Review
Process, 51 FOOD & DRUG L.J. 651, 654-59 (1996) (arguing that FDA suffers from "an institutional
culture that breeds risk avoidance and an autocratic style of regulation").
265 See Shalala, 953 F. Supp. at 528.
266 Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 108 Stat.
4325 (codified as amended in scattered sections of 21 U.S.C.) [hereinafter DSHEA].267 See Gayle Hanson, FDA and Vitamins: Bitter Pill or good Rx?, WASH. TIMES, Nov. 18,
2003, at A12 (detailing efforts of opposition on Capital Hill).
268 See Peter A. Vignulo, The Herbal Street Drug Crisis: An Examination of the Dietary
Supplement Health and Education Act, 21 SETON HALL LEGIS. J. 200, 216-17 (1997). For instance,
the Nutrition Health Alliance hired Anthony T. Podesta, former aide to Edward M. Kennedy (D-MA),
the Chairman of the Senate Labor and Human Resources Committee, to spearhead the group's
lobbying efforts. See Dante E.A. Ramos, Vitamin Makers Try a Dose of Lobbying, 25 NAT'L HEALTH
J. 1879 (1993).
269 The process began in the Senate Labor and Human Resources Committee, where DSHEA
passed 12-5, over the objection of Chairman Edward M. Kennedy. See Smith, supra note 186.
270 140 CONG. REC. S 14,798-800 (daily ed. Oct. 7, 1994).
271 Congressional Findings of Fact, reprinted in Pub. L. No. 103-417 § 2 (1994), 108 Stat.
4325 (2004).
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First, DSHEA ensured that most dietary supplements would not require pre-
market testing for safety and efficacy.272 Indeed, DSHEA largely preempts the
FDA's proposed rules to treat food products and dietary supplements identically.
273
DSHEA also amends the FDCA to distinguish dietary supplements as non-food
additives and, depending upon particular product claims, as non-pharmaceutical
drugs.2 74 This is true even when dietary supplements contain ingredients identical to
those used in food additives or pharmaceutical drugs.275
Equally important, DSHEA significantly expands the statutory definition of
"dietary supplement" beyond essential nutrients. 276 Specifically, DSHEA defines a
dietary supplement as:
[any] product (other than tobacco) intended to supplement the diet that
bears or contains one or more of the following ingredients:
(A) a vitamin;
(B) a mineral;
(C) an herb or other botanical;
(D) an amino acid;
(E) a dietary substance for use by man to supplement the diet by
increasing the total dietary intake; or
(F) a concentrate, metabolite, constituent, extract, or combination of
any ingredient described in clause (A), (B), (C), (D), or (E). 277
As a result, substances such as fish oils, ginseng, garlic, and combinations thereof
receive the comparatively relaxed regulatory treatment. This looser definition
particularly benefits herbal supplement manufacturers, whose products often contain
nonnutritive ingredients.
278
DSHEA similarly benefits dietary supplement manufacturers by not requiring
them to register with the FDA or to report adverse events from product usage, thus
treating them akin to food manufacturers. 279  The Public Health Security and
Bioterrorism Preparedness and Response Act of 2002280 ("Bioterrorism Act of
2002"), however, provides the FDA with additional regulatory authority over both
272 Although there is no general requirement for manufacturers of dietary supplements to
submit evidence of product safety to the FDA before marketing a product, there exists "a 75-day pre-
market notification requirement for manufacturers or distributors of dietary supplements that contain
'new dietary ingredients' that were not marketed in the U.S. before October 15, 1994, unless the
supplement contains only ingredients that have been present without chemical alteration in the food
supply as an article used for food." Center for Food Safety and Applied Nutrition Director Comments
on Status of Dietary Supplements in U.S., State News Service: Hearing on Ten Years After the
Implementation of DSHEA: The Status of Dietary Supplements in the United States, Before the House
Comm. on Government Reform, Subcomm. On Human Rights and Wellness, 108th Cong., Mar. 23,
2004, available at LEXIS News Wire (statement of Robert E. Brackett, Ph.D., Director Center for
Food Safety and Applied Nutrition, Food and Drug Administration, Department of Health and Human
Services) (hereinafter Statement of Robert E. Bracket].
273 DSHEA § II (voiding 58 Fed. Reg. 33,690 (June 19, 1993)).
274 Id. at § 3(b) (codified as amended at 21 U.S.C. § 321(s)(6) (2000)).
275 Id. at § 3(b)(3) (codified as amended at 21 U.S.C. §§ 321(s)(6), 321(ff)(3)(A)); see also
Joshua A. Beisler, Dietary Supplements and Their Discontents: FDA Regulation and the Dietary
Supplement Health and Education Act of 1994, 31 RUTGERS L.J. 511, 515 (2000).
276 See Gilhooley, supra note 168, at 682.
277 DSHEA § 3.
278 See Gilhooley, supra note 168, at 682.
279 See Statement by Robert E. Brackett, supra note 272.
280 Pub. L. No. 107-188, 116 Stat. 694 (2002) (codified in scattered sections of 42 U.S.C.).
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types of manufacturers, and it requires manufacturers to register their processing
facilities.28' On the other hand, dietary supplements, like food products, may be
removed from the market only if the FDA determines that they contain "poisonous
or deleterious" substances.282 This standard has remained since 1906, as neither
DSHEA nor other legislation has imposed a stricter one. 83
DSHEA also affords wide latitude to dietary supplement label claims, treating
them with only slightly greater scrutiny than food label claims.284 Indeed, provided
supplement products bear a cursory label disclaimer, 285 DSHEA exempts them from
FDA pre-authorization of "structure/function" claims (such as "Calcium builds
strong bones"), which involve the way in which a nutrient affects the function or
structure of the body.286 More broadly, DSHEA enables supplement companies to:
(1) "claim[] a benefit related to a classical nutrient deficiency disease and
disclose[] the prevalence of such disease in the United States";
(2) "describe[] the role of a nutrient or dietary ingredient intended to affect
the structure or function in humans";
(3) "characterize[] the documented mechanism by which a nutrient or dietary
ingredient acts to maintain such structure or function"; and
(4) "describe[] general well-being from consumption of a nutrient or dietary
ingredient.,
287
This discretion includes the capacity to promote a product's alleged "affect [on]
the structure on function in humans, '288 as well as its capacity to "support a healthy
heart," "protect cells from damage," and "improve the function of a comprised
immune system," regardless of whether the product definitively performs such
functions. 289  From a practical perspective, supplement companies may use any
language to promote the functional and structural benefits of their products, as long
as the text is not misleading or false.
290
On the other hand, DSHEA invited regulatory clarity on ingredient content and
levels of vitamins and minerals appearing on product labeling. Beginning in March
281 21 U.S.C. § 350d(a)(l) (Supp. 2002).
282 21 U.S.C. §§ 342(a), (f) (Supp. 2002).
283 As noted by Professor Hutt, although DSHEA did clarify the "poisonous or deleterious"
substance standard by providing that any food or supplement is only deemed to be adulterated if it
may be injurious to health under the conditions of use recommended or suggested on the labeling,
"this difference is of no practical importance because the Supreme Court had adopted a similar
interpretation of the provision as early as 1914 and that decision has remained unchanged ever since."
See Peter Barton Hutt, FDA Statutory Authority to Regulate The Safety of Dietary Supplements (draft
of forthcoming article, Oct. 3, 2004, on file with author) (21 U.S.C. § 342(f) and United States v.
Lexington Mill & Elevator Co., 232 U.S. 399 (1914), respectively).284 Labels on conventional food can make structure/function claims without any disclaimer.
285 21 U.S.C. § 343(r)(6)(C) (stipulating that the product labels must include the following
language: "This statement has not been evaluated by the Food and Drug Administration. This product
is not intended to diagnose, treat, cure, or prevent any disease").
286 21 U.S.C. § 343(r)(6). A structure/function claim is permitted so long as the FDA is
notified, the manufacturer has substantiation that the claim is truthful and not misleading, and the
product contains a disclaimer. The following disclaimer must accompany structure/function claims:
"This statement has not been evaluated by the Food and Drug Administration. This product is not
intended to diagnose, treat, cure or prevent any disease." Shalala, 953 F. Supp. at n.l I (citing 21
U.S.C. § 343(r)(6)(C) (1994)).287 21 U.S.C. § 343(r)(6).
288 21 U.S.C. § 342(r)(6).
289 The product claims refer to products "CardiAll," "Liverite," and "Resist," respectively. See
Specter, supra note 94.
290 See Robert G. Pinco & Paul D. Rubin, Ambiguities of the Dietary Supplement Health and
Education Act of 1994, 51 FOOD DRUG L.J. 383, 385 (1996).
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1999, and pursuant to implementing FDA regulations, dietary supplement labels
were required to display a "Supplement Facts" panel similar to the "Nutrition Facts"
panel on most processed foods.291 These panels mandate a listing of all dietary
ingredients present in a product, and when certain nutrients, such as Vitamin C,
calcium, and iron, are present in significant levels, supplement manufacturers must
provide the daily-recommended percentage.
292
DSHEA also initially preserved the NLEA's more stringent standard for
supplement (and food) health claims, including those pertaining to specific disease
treatment. Indeed, in enacting DSHEA, Congress created the Commission on
Dietary Supplement Labels ("DSHEA Commission") to identify optimal regulatory
language for supplement health claims, particularly in comparison to food and drug
health claims. The findings of the Commission were accorded significant weight,
since DSHEA mandated that the FDA issue timely regulations in response to any
Commission recommendation; failure to do so would have exempted all dietary
supplements from the basic NLEA requirements.
2 93
In response to Congress' directive, the Commission largely affirmed that health
claims for dietary supplements, like those for food products, should require
premarket approval based on significant scientific agreement. 94 The Commission
reasoned that consumers are likely to be as confused by supplement health claims as
by food and drug health claims.295 Significantly, however, the Commission also
endorsed greater involvement by outside experts in the FDA review process of
supplement health claims. 296 As discussed in this Article, the scope of the FDA
health claim review process would prove unsettled for years to come, often resulting
in uncertain signals for consumers assessing risk and benefit.
IV. POST DSHEA & CONSUMER INTERACTION WITH DIETARY
SUPPLEMENTS
A. MARKET MANIPULATION & CONSUMER UNCERTAINTY THROUGH LEGISLATIVE
AMBIGUITY & ADMINISTRATIVE VARIANCES
Once signed by President Clinton, DSHEA became a rare political volleyball
without discernable partisan affiliation. Indeed, supporters from across the spectrum
championed it as a victory for consumer freedom, populist protection, and
291 See Food Labeling; Statement of Identity, Nutrition Labeling and Ingredient Labeling of
Dietary Supplements, 60 Fed. Reg. 67,194, at 67,205 (Dec. 28, 1995) (codified at 21 C.F.R. pt. 101);
see also 62 Fed. Reg. 49,826 (Sept. 23, 1997) (codified at 21 C.F.R. pt. 101) (explaining that
"supplement facts" was chosen instead of "nutrition facts" because with "nutrition facts ... the
information presented, at least in part, is about nutrition, or because these products are marketed for
their nutritional value. The nutritional value of a particular product does not determine whether it is a
dietary supplement or a conventional food. Many dietary supplements contain many DV-nutrients;
many contain none.").
292 See Overview of Dietary Supplements, FDA, Jan. 3, 2001, at
http://vm.cfsan.fda.gov/-dms/ds-oview.html; 62 Fed. Reg. 49,825, at 49,849 (Sept. 23, 1997)
(codified at 21 C.F.R. pt. 101).
293 See DSHEA § 12(e)(3); see also Gilhooley, supra note 168, at n. 87 (explaining the
significance of the Commission on FDA rulemaking).
294 See REPORT OF THE COMM'N ON DIETARY SUPPLEMENT Labels at 30 (Nov. 1997),
available at http:/lwww.health.gov/dietsupp/ .
295 Id. at 34.
296 Id. at 35; see also FDLI meeting reviews US dietary supplements legislation, 2
NUTRACEUTICALS INT'L (1997) (noting how the DSHEA Commission recommended that the FDA
improve the process by encouraging external input from scientists and governmental experts).
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preventative medicine. For instance, Senator Tom Harkin predicted that, by
promoting supplements' preventive qualities, DSHEA would diminish national
healthcare costs. 29 7 Similarly buoyant, President Clinton reveled in the replacement
of a regulatory framework where "agencies of government charged with promoting
the food supply and the rights of consumers have paradoxically limited the
information to make healthful choices in an area that means a great deal to over 100
million people. 298
Others, however, viewed DSHEA more guardedly. Most telling, the Center for
Science in the Public Interest forecasted "America's Second Age of Quackery.,
299
In other quarters, DSHEA became emblematic of an increasingly de-regulated
society, where the interests of consumers are dwarfed by those of large industries.3 ° °
Perhaps DSHEA's greatest critics were FDA administrators, who were said to regard
it as a detrimental reversal of effective regulatory philosophies-a viewpoint which
may have diminished their initial commitment to regulatory implementation.30'
Notwithstanding rhetorical flourish, DSHEA has discernibly promoted a
regulatory framework whereby product effectiveness and risk are largely unknown
to consumers.30 2 Indeed, since passage of DSHEA, supplements have increasingly
fallen under the regulatory radar. 30 3  Though some consumers uncover relevant
information through informal research methods, such as Internet searches or
consultations with medical clinicians, the vast majority remains uninformed,
typically until a group of product users suffers health complications that generate
media attention or, more seldom, FDA action.
Along those lines, many Americans express obliviousness to the considerable
regulatory variances among food, drugs, and dietary supplements. Indeed, most are
unaware that, while pharmaceutical drugs receive extensive FDA pre-market testing
to verify safety and efficacy, dietary supplements do not.30 4  Such unawareness
likely correlates to consumer linkage of drugs and supplements as functionally akin
products, with both presumptively designed to sustain or improve the state of one's
health.30 5  Consumer expectations, therefore, suggest that efficacious regulation
would treat dietary supplements more like drugs than food.
297 140 Cong. Rec. S14780 (daily ed. Oct. 7, 1994).
298 DSHEA: Statement by President Clinton Upon Signing S. 784, 1995 U.S.C.C.A.N. 3523-1
(Oct. 25, 1994). President Clinton also heralded how "manufacturers, experts in nutrition, and
legislators, acting in a conscientious alliance with consumers at the grassroots level, have moved
successfully to bring common sense to the treatment of dietary supplements under regulation and
law." Id.
299 See Smith, supra note 186.
300 See Gilhooley, supra note 168, at 666 (noting that "the term 'being DSHEAed' has become
a popular byword for deregulation"); see also Nestle, supra note 147, at 233 (describing concerns of
potential quackery generated by DSHEA).
301 See NPR Transcript, supra note 237 (quoting Annette Dickinson, head of the Supplement
Trade Association, the Council for Responsible Nutrition.); see also Robert G. Pinco & Todd H.
Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Government Regulation
Five Years After Enactment of the Dietary Supplement Health and Education Act of 1994, 54 FOOD
DRUG L.J. 567, 579 (1999) (noting that DSHEA surprised the FDA).
302 See Sara Schulman, Addressing The Potential Risks Associated with Ephedra Use, 118 PUB.
HEALTH REP. 487, 492 (2003).
303 See NPR Transcript, supra note 237 (quoting Annette Dickinson, head of the Supplement
Trade Association, the Council for Responsible Nutrition.).
304 See Arthur P. Goldman, Unregulated Herbal Remedies-an Accident Waiting to Happen,
CHI. TRIB., Dec. 24, 2002, at C19 (Professor Goldman noting that most Americans are unaware that
dietary supplements do not receive premarket testing).
305 See supra at Part III.C.
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Regulatory variances triggered by DSHEA have also influenced industry
behavior, particularly in regards to manufacturers' bargaining leverage with the
FDA. This is especially evident among manufacturers whose products might be
classified as food, drugs, or dietary supplements. Since DSHEA endorses a
minimalist regulatory approach to supplements, manufacturers are encouraged to
attempt to classify their products as supplements and thus avoid pre-market testing,
required disclosures, and prohibition on certain ingredients.
To best illustrate this phenomenon, consider Johnson & Johnson's efforts to
market Benecol, a margarine that may lower cholesterol levels, as a dietary
supplement rather than as a food or drug. 30 6  The FDA disagreed with such
classification, finding that Benecol's active ingredient, a plant sterol inhibiting
cholesterol absorption, represents an unapproved food additive that requires FDA
premarket approval.30 7 After lengthy negotiation, the FDA and Johnson & Johnson
agreed to a comprise whereby Benecol would be designated as a food rather than a
dietary supplement but would be GRAS and not subject to premarket approval.30 8
This outcome illustrates how, even when supplement manufacturers fail to receive
favorable classification under DSHEA, they appear emboldened by its presence, and
thereby gain a certain degree of negotiating leverage with the FDA that improves
their probability of lessened regulatory costs. For that later reason, supplement
manufacturers may project greater return on more "risky" products.
Consumer knowledge of supplement effectiveness and risk also appears
constrained by the uncertain regulatory treatment of supplement health claims,
which characterize the relationship of any substance to a disease or health-related
condition. 3°9 Indeed, discerning "health claims" from significantly less regulated
"structure/function claims" has sometimes proven unpredictable. Though certain
claims unambiguously comprise health claims, such as "fiber cures cancer," 310 others
appear murkier. For instance, consider the claim that a supplement "promotes non-
suicidal feelings." 31  Notably, this claim omits mention of specific disease, though
one might reasonably deduce that the product treats depression or similar mental
illness.
The murkiness of claim distinctions also promotes market manipulation of
labeling. Since passage of DSHEA, dietary supplement companies have often
secured and intensely promoted the "endorsement" of physicians, chiropractors, or
"nutrition experts. 312 This is not surprising, since studies confirm that, "to the
modem consumer, information labeled as 'scientifically proven' often assumes a
306 See Pat Kendall, Benecol: Cholesterol-Fighting Margarine, COLO. ST. U. COOPERATIVE
EXTENSION, Mar. 24, 1999, at http://www.ext.colostate.edu/pubs/columnnn/nn990324.html.
307 See Illene Ringel Heller, Functional Foods: Regulatory and Marketing Developments, 56
FOOD DRUG L.J. 197, 210-11(2001).
308 Id.
'0' See 21 C.F.R. § 101.14(a)(1) (2005); Deborah Pines, Time Limit on FDA Vitamin Review,
N.Y.L.J., Feb. 6, 1997, at 1. Such review could last an indeterminable period, particularly since the
FDA offered no fixed deadline to promulgate final regulations for a health claim. 21 C.F.R. §
101. 14(a)(1).
310 21 C.F.R. § 101.14(a)(l).
311 See Gilhooley, supra note 168 (mentioning this language as a useful illustration of
DSHEA's definitional murkiness).
312 See Patrick B. Massey, Be Wary of Supplements Labeled 'Proprietary Blend', CHI. DAILY
HERALD, Feb 16, 2004, at 5 (Dr. Massey is medical director for alternative and complementary
medicine for Alexian Brothers Hospital Network).
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posture of 'mystic infallibility.' 31 3 To illustrate, the manufacturer of Cartilade, a
dietary supplement made of shark cartilage, labeled its product with pictures of a
physician commonly associated with the claim that shark cartilage cures cancer.
3 14
Moreover, the mere allowance of "structure/function claims" appears to encourage
undesirable word parsing. For instance, a supplement label would include a "health
claim" if it claimed to reduce the onset of cataracts but would comprise a mere
"structure/function" claim if it asserted that the supplement "promotes healthy
vision." 315 Though the latter claim entails less specificity, a consumer may easily-
and mistakenly-assume the two claims represent similar therapeutic value.
The adequacy of dietary supplement consumer information appears likewise
disturbed by ongoing discord over the phrase "significant scientific agreement
among experts," which is required for health claim approval. Such discord
particularly relates to the First Amendment and its interplay with health claim
standards. Indeed, some contend that commercial speech jurisprudence offers the
most salient justification for consumer access to dietary supplements, since First
Amendment commercial speech cases tend to favor informed consumer choice over
316government imposed limitations.
These ideas were tested in Pearson v. Shalala,317 where a dietary supplement
manufacturer challenged the FDA's refusal to authorize health claims for failing to
demonstrate the requisite significant scientific agreement.3 18 On appeal, the U.S.
Court of Appeals for the District of Columbia upheld the concept of premarket
approval for health claims 319 but invalidated the specific FDA standard since it
imposed a higher standard than permitted by the First Amendment.32 ° Indeed, the
court noted that in enacting DSHEA, Congress intended to broaden consumer
freedom in choosing safe supplements. 32' Moreover, in holding that supplement
health claims comprise qualified commercial speech and thus warrant constitutional
protection, the court directed the FDA to allow statements of preliminary scientific
findings. In 2003, the FDA announced that it would consider "qualified health
claims," which comprise more guarded claims based on less than significant
scientific agreement.322 Nevertheless, the FDA continues to contemplate how to best
implement Pearson, leaving a certain degree of uncertainty for dietary supplement
consumers as to the extent to which they can rely on supplement health claims.
Even when health claims are indisputably discernable, the FDA possesses
limited purview over dietary supplement advertising. As stipulated in the FDCA,
FDA authority to regulate claims is restricted to product label content, which
313 See Charles J. Walsh & Marc S. Klein, From Dog Food to Prescription Drug Advertising:
Litigating False Scientific Establishment Claims Under the Lanham Act, 22 SETON HALL L. REv. 389,
392 (1992).
314 See United States v. Lane Labs-USA, Inc., 324 F. Supp. 2d 547 (D.N.J. 2004).
315 See Sally Squires, High Irony: New Supplement Labels are Short on Facts, WASH. POST,
Mar. 7, 2000, at Z14.
316 See Tom Valluck, Keeping Dietary Supplement Regulations Slim and Fit: Finding a Healthy
Balance between Paternalism and Consumer Choice, 2 GEO. J.L. & PUB. POL'Y 285, 300 (2004)
(citing Virginia State Bd. of Pharmacy v. Virginia Citizens Consumer Council, Inc., 425 U.S. 748
(1976); Pearson v. Shalala, 164 f.3d 650, 658 (D.C. Cir. 1999)).
317 14 F. Supp. 2d 10, (D.D.C., 1998), rev'd 164 F.3d 650 (D.C. Cir. 1999).
318 14 F. Supp. 2d at 10.
319 Pearson, 164 F.3d at 656.
320 Id. at 657.
321 Id. at 658.
322 See supra pp. 248-49.
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includes packaging, inserts, and other materials distributed at the point of sale.323 In
contrast, dietary supplement advertisements in books, magazines, mailings,
infomercials, and other television and radio commercials fall under the jurisdiction
of the Federal Trade Commission ("FTC") and its controlling law, the Federal Trade
Commission Act ("FTC Act").324 As a result, health claims in those settings escape
the purview of the FDA.
For a moment, consider variances between the FDA's and FTC's treatment of
supplement claims, and how such variances affect consumer information. While
manufacturers largely escape pre-market scrutiny of product label claims, FTC
standards require them to substantiate all performance, efficacy, and safety claims
used in advertising before releasing those claims to the public, and related claims
must be based on "competent and reliable scientific evidence. 325  Consequently,
consumers may internalize disparate messages for the same product, thus potentially
leading to confusion. Given optimism bias and other cognitive biases, it is also
plausible that many consumers might discount the more constrained advertising
information and accord greater weight to extravagant label claims. 326  In such a
setting, supplement manufacturers possess incentive to manipulate biases to lower
consumer appreciation of supplement risks. 327  Perhaps that explains why many
supplements do not contain ingredients listed on the label or contain ingredients that
are not listed.328
Cooperation between the FDA and FTC in regulating supplement claims has
improved in recent years, however, thus resulting in more stringent and proximate
standards. Indeed, since a 1971 inter-agency liaison agreement, the FDA and FTC
have expressed a willingness to cooperate on dietary supplement regulation. 329 In
fact, the FTC now accords "significant deference" to the FDA's scientific expertise,
even when a claim is subject to joint jurisdiction.330  Similarly, the FTC requires
323 See generally 21 U.S.C. §§ 321-393 (2000); see also 21 U.S.C. § 321(m) (defining the term
"labeling"); Pinco & Halpern, supra note 301, at 579 (distinguishing labeling from advertising).
324 See Federal Trade Commission Act, 15 U.S.C. §§ 45(a), 52, 55 (1972 & West Supp. 2004)
(prohibiting unfair or deceptive acts or practices in or affecting commerce, and false advertisements
for food, drugs, devices, services, or cosmetics in or affecting commerce); see also 59 Fed. Reg. 395,
409 (Jan. 4, 2004); FTC DIETARY SUPPLEMENTS ADVERTISING GUIDE FOR INDUSTRY (1998) (defining
advertising).
325 See Substantiation Policy Statement, appended to Thompson Medical Co., 104 F.T.C. 648,
839 (FTC, 1984); Deception Policy Statement, Letter Dated Oct. 14, 1983 from Commission to
Chairman John D. Dingell, appended to Cliffdale Associates, Inc., 103 F.T.C. 110, 174 (1984); 15
U.S.C. §§ 52, 55 (2000) (instructing advertisers to provide substantiated and accurate product
information).
326 This deduction appears consonant with research conducted by Dr. Kenneth Walker of
Toronto General Hospital, as he found that dietary supplement users tend to be most attracted to
certain cue words on labels, such as "natural" and "organic." See Kenneth Walker, Understand the
Facts about Ginkgo Biloba, CHI. SUN-TIMES, Apr. 2, 2000, at 8.
327 See generally, Hanson & Kysar, supra note 55, at 1427.
328 See supra p. 228.
329 See FTC-FDA Liaison Agreement, 4 Trade Reg. Rep. (CCH) PP9851-52 (1971); see also In
the Matter of Regulations on Statements Made for Dietary Supplements Concerning the Effect of the
Product on the Structure or Function of the Body; Proposed Rule, Comments of the Staff of the
Bureau of Consumer Protection of the Federal Trade Commission, Docket No. 98N-0044, Aug. 27,
1998 ("Their shared jurisdiction means that the two agencies coordinate closely to ensure that their
actions are consistent to the fullest extent feasible given the statutory authority of each"); see also
Sarah E. Taylor & Harold J. Feld, Promoting Functional Foods and Nutraceuticals on the Internet, 54
FOOD DRUG L.J. 423, 440-41 (1999) (explaining cooperation between the FDA and FTC in regulating
dietary supplement claims on the Internet).
330 See FTC Enforcement Policy Statement on Food Advertising, § III(A)(1) (May, 1994),
available at http://www.ftc.gov/bcp/policystmt/ad-food.htm.
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extraordinary evidence for health claims that either were rejected by the FDA or are
awaiting approval. 331 As discussed in Part B, misleading or unsubstantiated health
claims in supplement advertising comprise a burgeoning part of the FDA and FTC's
collaborative enforcement agenda. 332  In turn, consumers may benefit from
decreased cognitive biases.
B. CONSUMER DISRUPTIONS THROUGH ADVERSE EVENT REPORTING
With relatively minimal pre-market testing for the safety and efficacy of dietary
supplements, one might presume stringent standards once those products enter the
market. Such a presumption would prove largely inaccurate. Once dietary
supplements enter the market, the FDA monitors them through an adverse event
reporting system ("AER"). AER consists of voluntary and confidential reporting,
primarily from industry participants, health care providers, and consumers.333
Reporting may occur when an undesirable symptom is detected in an exposed
individual or a group of product users, though no established surveillance standard
exists to ensure reporting. 334 In the event of a report, the FDA may investigate, after
which they may pursue enforcement action, which can entail formal mechanisms
(e.g. seizure; injunction) or informal ones (product recall; detention; warning
letter).335
The lack of mandatory AER reflects perhaps the greatest defect of DSHEA,
particularly when viewed in the prism of consumer information. Indeed, the
inspector general for the Department of Health and Human Services estimates that
the system reveals less than 1 percent of actual adverse reactions to dietary
supplements.336 Equally troubling, the FDA lacks the resources to expeditiously
review many of those reported adverse-reactions.337 Instead, the agency often has to
play "catch-up" to emerging problems, a predicament compounded by the sheer
proliferation of supplements on the market.338
The absence of pre-market testing and labeling guidelines only further
illuminates the defects inherent in AER. To illustrate, consider the plight of ephedra
weight-loss supplements in the American economy. Ephedra weight-loss
supplements derive from the desert plant "Ephedra equisetina," which, since at least
331 See Pinco & Halpern, supra note 301, at 581.
332 See The Food and Drug Law Institute's 45th Annual Educational Conference Keynote
Addresses, 57 FOOD DRUG L.J. 227, 239 (2002) (noting comments by Shelia F. Anthony,
Commissioner of the U.S. Trade Commission).
333 See FDA Backgrounder, How FDA Handles Problem Reports (Aug. 2003), available at
http://www.fda.gov/opacom/backgrounders/report.html.
334 See Panel Offers Recommendations for Monitoring Adverse Events from Dietary
Supplements, Life Sciences Research Office (Nov. 15, 2004), available at http://www.innovations-
report.de/html/reports/medicine health/report-36264.html.
335 See Department of Health and Human Services, Office of the Inspector General, Adverse
Event Reporting for Dietary Supplements: An Inadequate Safety Valve, OEI-01-00-00180, at 16 (Apr.
2001) (quoting Annual Industry Overview 2000, NUTRITION Bus. J., at 4).
336 See John A. McDonald, Dietary Aids Facing Scrutiny, HARTFORD COURANT, May 5, 2003,
at Al.
337 See Department of Health and Human Services, Office of the Inspector General, supra note
335, at 16.
338 This viewpoint is often expressed by FDA administrators. For instance, Christine Taylor,
director of the FDA's Office of Nutritional Products, Labeling and Dietary Supplements, finds "the
government does bear a considerable burden in post-marketing world." McDonald, supra note 336.
252 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 31 NO. 2&3 2005
3000 B.C.,339 has been used in China as a stimulant and bronchodilator under its
traditional name "Ma huang." 340  Ephedra has also been routinely misused as a
herbal substitute for hallucinogenic amphetamine MDMA, or "ecstasy. 34' It has
also been marketed in tea form, usually to treat patients with asthma and respiratory
conditions, 342 or, less often, to "cure" sexually transmitted diseases.
343
In the United States, ephedra has been used primarily to stimulate weight loss
and boost athletic performance. 34  From 1993 to 2003, the FDA received 2,277
adverse event reports from ephedra users, with such symptoms as nausea, vomiting,
anxiety, hypertension, tremors, and palpitations commonly noted.345  Far less
frequently, use of ephedra has been associated with heart attacks, seizures, stroke,
and death.346
Beginning in 1996, several states began to enact requirements for ephedra
product labels in response to growing concerns over ephedra's safety.34 7 Those
requirements mandated warnings be placed on ephedra supplement labels.
Following the well-publicized, ephedra-related death of Baltimore Orioles pitcher
Steve Belcher in 2003,348 the FDA proposed that warning language be mandated on
all ephedra supplement labels.349 In December 2003, the FDA ordered the removal
of all ephedra supplements from the market, concluding that supplements containing
ephedrine alkaloids presented an unreasonable risk of illness or injury. 350 By that
time, ephedra had been linked to 155 deaths and 16,000 adverse reactions.
351
Notably, however, the FDA imposed no restriction on the sale of conventional foods
339 See FDA Hires Contractor to Handle Information Requests in its Adverse Events Reports
AER System, FOOD CHEMICAL NEWS, June 7, 1999 (citing remarks by Daniel Mowrey of the
American Phytotherapy Research Laboratory).
340 See Jun P. Tagalog, P3.6B Worth of Illegal Drugs Seized in Cebu, BUSINESSWORLD , Mar.
18, 2004, at 12.
341 Id
342 Interview with Dr. Andrew Weil, CNN TRANSCRIPTS, Mar. 20, 2004, available at LEXIS
News Library, CNNTRN file (citing comments by Dr. Weil, director of the Integrated Medicine
Program at the University of Arizona).
343 ANDREW CHEVALLIER, THE ENCYCLOPEDIA OF MEDICINAL PLANTS (1996) (noting that in
the 1800s, ephedra was thought to cure gonorrhea and syphilis).
344 See Schulman, supra note 302.
345 U.S. General Accounting Office, Dietary Supplements Containing Ephedra: Health Risks
and FDA's Oversight, Testimony before the House Subcommittee on Oversight of and Investigations
(July 23, 2003), available at http://www.gao.gov/new.items/d03lO42t.pdf.
346 See Schulman, supra note 302.
347 Id.
348 Brody Mullins, Ephedra Battle Heats Up, ROLL CALL, Mar. 12, 2003, at 1. available at
LEXIS, News Library, ROLLCL file.
349 U.S. Department of Health and Human Services, Dietary Supplements Containing
Ephedrine Alkaloids; Reopening of the Comment Period, Docket no. 95N-0304, Feb. 28, 2003,
available at http://www.fda.gov/OHRMS/DOCKETS/98fr/95n-0304-nprOOO3.pdf (including the
following: "WARNING: Contains ephedrine alkaloids. Heart attack, stroke, seizure, and death have
been reported after consumption of ephedrine alkaloids. Not for pregnant or breast-feeding women or
persons under 18. Risk of injury can increase with dose or if used during strenuous exercise or with
other products containing stimulants (including caffeine). Do not use with certain medications or if
you have certain health conditions. Stop use and contact a doctor if side effects occur.").
350 Lester M. Crawford, Remarks of the Acting FDA Commissioner: FDLI's 47th Annual
Conference, 59 FOOD DRUG L.J. 201, 206 (2004). After a three-month grace period, ephedra became
an adulterated food as well as an unapproved and misbranded drug in February 2004. Final Rule
Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an
Unreasonable Risk, 69 Fed. Reg. 6788 (Feb. 11, 2004) (to be codified at 21 C.F.R. pt. 119) (declaring
dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable
risk of illness or injury).
351 Virginia Anderson, Risky Ephedra Banned, ATLANTA J. CONST., Dec. 31, 2004, at IA.
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containing ephedra, such as herbal tea.352 Critics immediately complained of undue
influence by the pharmaceutical industry and claimed that the vast majority of
persons using ephedra encountered no discernable side-effects while perceiving
significant bodily enhancement. 353 Nevertheless, the FDA, along with federal law
enforcement agencies, have since employed great efforts to remove ephedra-
containing dietary supplements from the open market.
354
Though media reports have often characterized ephedra as "deadly," 355 actual
harm inflicted by the substance remains a source of debate. Clinical studies
generally confirm a relationship between ephedra use and negative health
consequences, 356 although a significant minority suggests a less certain nexus,
particularly when ephedra is used in recommended doses.357  Indeed, NVE
Pharmaceuticals of New Jersey, the maker of the ephedra supplement called
"Stacker 2," sued the FDA in March 2004, contending that the agency lacked proof
that the stimulant is dangerous when used as directed. 358  Recent case law
strengthens this latter viewpoint. In Nutraceutical Corporation v. Crawford,359 the
U.S. District Court for the District of Utah ruled that low-dose ephedra products do
not present unreasonable risk or danger to consumers.360 Pending possible appeal,
Nutraceutical Corporation dictates the removal of the FDA ban on low-dose
ephedra products, though such a ban remains in effect for ephedra products of higher
dose. 3 6 ' Nevertheless, many in the scientific community insist that consumption of
ephedra often proves harmful. Consider, for instance, a recent study published in the
Annals of Internal Medicine, which claims that, although ephedra comprised less
than one percent of the herbal supplement market from 1993 to 2002, it accounted
for 64 percent of adverse reactions to such supplements.
362
Of more certain concern is staggering evidence that ephedra manufacturers
concealed the vast majority of consumer complaints. Indeed, two of the leading
manufacturers, E'ola and Metabolife, failed to voluntarily report over 15,000
complaints, over ten percent of which involved deaths, heart attacks, strokes,
352 Phil Wallace, Court Challenge Seeks to Overturn FDA's Ban Reasoning, FOOD CHEMICAL
NEWS, Dec. 13, 2004, at 12.
353 Id.
354 Most recently, in November 2004, the United States Attorney for the Southern District of
Texas in U.S. District Court in Houston filed a complaint charging that VITERA-XT, an ephedra-
containing dietary supplement marketed by Houston-based Asia MedLabs, Inc., represents an
adulterated food as well as an unapproved and misbranded drug which presents an unreasonable risk
of illness or injury. FDA Acts to Remove Ephedra-Containing Dietary Supplements From Market,
FDA Press Releases, Nov. 23, 2004, available at LEXIS News Library, ALLNEWS file.
355 See, e.g., Jennifer Heldt Powell, Feds Circle Date for Ephedra Ban, BOSTON HERALD, Feb.
7, 2004, at 30.
356 See, e.g., Christine A. Hailer & Neal L. Benowitz, Adverse Cardiovascular and Central
Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids, 343 N.
ENGL. J. MED. 1833-38 (2000); D. Samenuk et al., Adverse Cardiovascular Events Temporally
Associated with Ma Huang, an Herbal Source of Ephedrine, 77 MAYO CLIN PROC 12-16 (2002).
357 See, e.g., C.N. Boozer et al., Herbal Ephedra/Caffeine for Weight Loss: A 6-Month
Randomized Safety and Efficacy Trial, 26 INT'L J. OBESITY 610 (2002).
358 Health Highlights, CONN. POST, Apr. 12, 2004.359 No. 2:04CV409 TC, 2005 WL 852157 (D. Utah Apr. 13, 205).
360 Id.
361 See Penni Crabtree, Experts Debating Scope of Decision, SAN DIEGO TRIB., Apr. 16, 2005,
at C1 (citing remarks by Kimberly Rawlings, an FDA spokeswoman). At the time of this writing, the
Acting U.S. Solicitor General, Paul D. Clement, is considering whether to appeal.362 See Stephen Bent et al., The Relative Safety of Ephedra Compared with Other Herbal
Products, 138 ANNALS AM. MED. 1006 (2003).
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seizures, chest pains, and heart rhythm disturbances.363 Such behavior appears
consonant with manufacture incentive to distort cognitive biases and lower
appreciation of product risks.36 4  The lack of regulatory deterrence also likely
encouraged such behavior: The FDA's decision to remove ephedra represented the
first time the FDA has ordered a dietary supplement pulled from the market since
passage of DSHEA.365
C. CONTRASTING AMERICAN TREATMENT OF DIETARY SUPPLEMENTS TO EUROPEAN
DIETARY SUPPLEMENT REGULATIONS AND PRIVATE ENFORCEMENT
MECHANISMS
The relaxed regulatory treatment of dietary supplements appears striking when
compared to the regulatory treatment of those products in other communities. This
is especially detectable when observing the treatment of dietary supplements within
the European Union ("EU"). Indeed, the Commission of the European Community
requires "results of tests and trial on quality, safety and efficacy" of each supplement
before the supplement can enter the EU's stream of commerce. 366 Moreover, the EU
recently passed the similarly restrictive Directive 2002/46/EC ("Directive"), which
establishes maximum permissible doses for vitamin and mineral supplements and
harmonized rules for product labeling. 367 Such labeling requirements include the
following: a stem warning of health risks for excess usage; the comment "This is not
a medicinal product"; and an admonition that the product be stored out of the reach
of young children. 368 The Directive, which will be implemented by August 2005,
also prohibits a wide array of supplement ingredients, including Vitamin E and the
mineral boron, which is commonly contained in supplements designed to advance
women's health.3 69
The "Precautionary Principle" in part explains disparities in governmental
regulation of dietary supplements in Europe and the United States. The Principle,
which posits that preventative measures should be employed whenever there exists
inconclusive scientific information or indications of harm from a particular behavior,
363 See Dietary Supplement Safety: Hearing Before the Senate Governmental Affairs
Subcommittee on Oversight of Government Management, FED. DOC. CLEARING HOUSE CONG.
TESTIMONY, June 8, 2004 (testimony of Mr. Charles Bell Program Director, Executive Office,
Consumer Reports (available at LEXIS, Nexis Library, CNGTST file.
364 See Hanson & Kysar, supra note 55.
365 See Judy Sarasohn, A Departure from the Proscribed Path, WASH. POST, Jan. 22, 2004, at
A23.
'66 COMMISSION OF THE EUROPEAN COMMUNITY, Proposal for a Directive of the European
Parliament and of the Council Amending the Directive 2001/83/EC As Regards Traditional Herbal
Medicinal Products (2002), available at
http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2OO2/janv/com20 0 2_ I _en.pdf.
367 Long Wait Ahead For EU Supplements Industry on Maximum Doses, NUTRACEUTICALS
INT'L, July 1, 2004 (noting that the European Union is now negotiating tolerable upper intake levels
for the substances, and that process will continue until April 2005), available at LEXIS, News
Library, NUTINT file. However, the European Court of Justice recently ruled that classifying dietary
supplements as medicines if they contained more than one or three times the Recommended Daily
Allowance for the relevant vitamins or minerals constituted a barrier to the free movement of goods
across the EU. Id.
368 Sidley Austin Brown & Wood LLP, International National Products Regulation Q&A:
What Effect do They Really Have on the U.S.?, available at
http://www.nnfa.org/services/govemment/pdf/CodexEUdir.pdf (last visited Jan. 8, 2005).
369 Kathrin Jungbeck, Food Supplements Directive Set to Overhaul Europe, EUROMONITOR
INT'L, June 15, 2004, available at http://www.euromonitor.com/article.asp?id=3258 (last visited Jan.
8, 2004).
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has achieved far greater salience within European countries than in the United
States. 370  In essence, the Principle endorses a risk-averse philosophy to product
availability within free markets, suggesting that such products should not be
introduced until they are proven safe. 37 1 Although "risk" is not prescribed absolute
value in precautionary principle assessments,372 manufacturers bear a far greater
burden when convincing policy-makers of product safety, particularly since product
benefit receives diminished priority.
373
The contrasting philosophy of tolerable risk found in European dietary
supplement policies accentuates the industry-accommodating features of DSHEA.
Indeed, by imposing discernibly less taxing requirements on manufacturers, DSHEA
evinces greater policy worth in consumer access to products than in product efficacy
or consumer safety. 374 DSHEA also appears to reflect normative variances between
European and American consumer protection ideals: it is thought that European
preference for the Precautionary Principle manifests a broader desire for risk-utility
analysis, while even American consumer advocates often endorse a less-protective
''consumer expectation standard," which considers effect on "the reasonable
consumer."375  These conclusions may be deduced from the treatment of
supplements by individual European countries as well. For instance, Germany treats
any supplements containing herbs as prescription drugs, a profound variance from
the libertarian model inherent in DSHEA.376
On the other hand, might the relaxed regulatory treatment of dietary
supplements in the United States also reflect sufficient private deterrents?
Intriguingly, despite the infamy of several supplements, the vast majority appear
remarkably benign, notwithstanding their uncertain effectiveness and often-
mislabeled ingredient content. This may suggest that forces within the dietary
supplement industry, such as voluntary certification programs or industry
watchdogs, augment tepid governmental regulation of supplements.
Indeed, since passage of DSHEA, several private organizations have created
voluntary certification programs to monitor industry behavior. For instance, the
United States Pharmacopoeial Convention sets standards for some nutrients,
including quality control, good manufacturing practices, and assurances that
370 Communication from the Commission on the Precautionary Principle, Commission of the
European Communities, COM (2000), Feb. 2, 2000, at 7; see also George E.C. York, Global Foods,
Local Tastes & Biotechnology: The New Legal Architecture of International Agriculture Trade, 7
COLUM. J. EUR. L. 423, 443-46 (2001) (explaining usage of the precautionary principle in Europe).
371 Wilson Huhn, Three Legal Frameworks for Regulating Genetic Technology, 19 J.
CONTEMP. HEALTH L. & POL'Y 1, 33 (2002).
372 See, e.g., U.N. Conf. on Env't and Dev., Rio Declaration on Env't and Dev., Principle 15,
U.N. Doc. A/Conf. 151/5 (1992), reprinted in 31 I.L.M. 874 (1992) (finding that lack of absolute
scientific certainty should not impair "cost effective measures" when those measures do not appear
harmful); see also Sarah Lively, The ABCs and NTBs of GMOs: The Great European Union-United
States Trade Debate-Do European Restrictions on the Trade of Genetically Modified Organisms
Violate International Trade Law?, 23 N.W. J. INT'L L. & Bus. 239, 246-248 (explaining limits of the
Precautionary Principle in the EU).
373 Volkert Dethlefsen et al., The Precautionary Principle: Towards Anticipatory
Environmental Management, in CLEAN PRODUCTION STRATEGIES 41, 41-62 (Tim Jackson ed., 1993).
374 Paula Fitzgerald Bone & Karen Russo France, International Harmonization of Food and
Nutrition Regulation: The Good and the Bad, 22 J. PUBLIC POL'Y & MKTG. 102 (2003).
375 See generally Geraint G. Howells & Mark Mildred, Is European Products Liability More
Protective than the Restatement (Third) of Torts: Products Liability?, 65 TENN. L. REV. 985 (1998);
see also Douglas A. Kysar, The Expectations of Consumers, 103 COLUM. L. REV. 1700 (2003)
(explaining the role of the consumer expectations test in American jurisprudence).
376 Jane E. Allen, No Minor Mix-up, L.A. TIMES, Jan. 10, 2000, at I.
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products match label claims and contain digestible ingredients.377 Participating
companies which demonstrate integrity, potency, and purity within their products
may place a "USP-Verified" seal on their products' labels.378 Similarly, the National
Sanitation Foundation, which includes representatives from academia, government
agencies, and manufacturers, not only tests the accuracy of supplement claims, but
also periodically audits participating manufacturers to insure continued quality
control. Like the "USP-Verified" seal, compliant manufacturers earn NSF-
certificates, which they may use as marketing devices. 379 By rewarding compliant
behavior, private monitoring incentivizes the production of quality products.
Moreover, seals communicate meaningful information to consumers for selecting
dietary supplements: those containing a label seal have been recognized as
legitimate and safe by a third party.
Perhaps more effective than voluntary certification programs are industry
watchdogs, since they may evaluate any product on the market. To illustrate,
consider ConsumerLab.com, which regularly tests dietary supplements containing
herbs. The company has revealed that 40 percent of herbal supplements do not
contain the active ingredients listed, while many others contain less or more of a
particular ingredient listed or simply contain the wrong herb.38 ° Indeed, research
conducted for ConsumerLab.com and similar watchdogs reveals wide variability in
supplement ingredients, with active ingredients often proving inconstant,
unpredictable, or simply unknown. 38 l This is especially troublesome for children,
who, by virtue of their smaller size and diminished capacity for detoxifying
chemicals, are more susceptible to the effects of dosage variations. 382 Thus, industry
watchdogs can illuminate vital deficiencies among the entire spectrum of dietary
supplements, thereby enhancing consumer choice.
Lastly, market inducements for self-policing among dietary supplement
manufacturers affect industry practices. For instance, negative publicity of any
383dietary supplement product may adversely affect sales of other supplements.
Along those lines, studies suggest that recent fallout from the ephedra controversy
has slowed the growth of the supplement industry and caused consumers to become
warier of all supplement products. 384 A more skeptical societal view of dietary
supplements might also increase the prospect of civil litigation for a wider scope of
industry actors.385 For these reasons, supplement manufacturers have initiated
collaborative self-policing efforts. To illustrate, consider that industry suasion has
377 See generally U.S. Pharmacopoeia, http://www.usp.org/ (last visited Jan. 10, 2005).
378 U.S. Pharmacopoeial Convention, Dietary Supplements, available at
http://www.usp.org/dietarySupplements/ (last visited Jan. 8, 2005).
379 Judy Packer-Tursman, Certified, to a Point, WASH. POST, Nov. 19, 2002, at FOI (citing
industry research finding that when a consumer is given the choice between two products, all other
things being equal, the consumer will select the product that has a credible third-party certification).380 See Allen, supra note 98.
381 See Woolf, supra note 54.
382 Id.
383 See Betsy Streisand, The Guru of Product Potential, N.Y. TIMES, Aug. 31, 2003, § 3, at I
(citing comments by Patrick D. Rea of the Nutrition Business Journal concerning the impact of
negative publicity on the entire dietary supplement market).
384 Id. (citing study by Nutrition Business Journal which found slowing industry growth and
citing comments by Patrick D. Rea of the Nutrition Business Journal concerning the impact of
negative publicity).
385 This phenomenon appeared in the tobacco litigations, as the industry's reputation
plummeted with a flurry of lawsuits, which only beget another series of litigations. See Lynn Mather,
Theorizing about Trial Courts: Lawyers, Policymaking, and Tobacco Litigation, 23 LAW & SOC.
INQUIRY 897, 935 (1998).
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increasingly convinced individual supplement manufacturers to standardize their
products, thus guaranteeing ingredient consistency among every capsule.386
Similarly, to resist regulatory encroachment by the FDA, larger supplement
manufacturers have lobbied smaller ones to provide explicit warning labels. 3
87
Although often informal and haphazard, self-policing among dietary supplement
manufacturers might impose a higher "cost" for market manipulation whenever
deviant actors are stigmatized, thus diminishing the frequency of such behavior.388
Though private enforcement mechanisms may partly fill the vacuum for dietary
supplement regulation, they have historically proven less effective than government
regulation. Indeed, they are often implemented on an ad hoc basis, with only some
dietary supplement manufacturers agreeing to cooperate. This is especially apparent
with voluntary certification programs, which attract only a minority of recent
entrants into the dietary supplement industry.389 Moreover, the very concept of
voluntary participation begs an important corollary: those manufacturers which
agree to external review of their products appear qualitatively different than those
which do not, thus evincing a predictive self-selection bias among participants.
Label certification might also mislead consumers into false deductions. For
instance, the USP-verified seal indicates that a product contains its stated ingredients
and that proper manufacturing practices were employed; a consumer, however, may
mistakenly believe that the seal also endorses the product's claims (e.g., "boosting
energy" or "enhancing memory"). 390  As a result, a consumer may derive false
confidence in a product and may purchase that product on false pretenses. 391 More
troubling, manufacturers may manipulate false deductions, particularly if conflicting
standards give rise to consumer confusion.392
For both methodological and structural reasons, industry watchdogs are
similarly restrained in their capacity to enhance consumer choice. First, they tend to
test mere samples of dietary supplement products, a procedure which fails to
contemplate frequent ingredient distortions within an individual product line. 393
Moreover, though industry watchdogs overcome self-selection bias by independently
selecting products for analysis, aversion to potential lawsuits deters them from
revealing the names of "flunking" products.394 Consequently, they tend to publicize
386 See Linda Saslow, Nassau Restricts Herbal Aids with Stimulant, N.Y. TIMES, Aug. 18,
1996, § 13L1, at I (citing comments by Gerard Mclntee, director of marketing for Nature's Plus, a
manufacturer of vitamins and herbs).
387 See Bruce Japsen, FDA Could Supplement Vitamin Regulation, CHI. TRIB., Sept. 6, 1998, at
IC.
38 This phenomenon has been evidenced among those industries where actors exploit cheap,
foreign labor. See William B. Sorbella, Less Developed Country as Start-up Corporation: Adopting
the Venture Capital Model for Development in Light of Global Capital Market Realities, 31 L. &
POL'Y INT'L Bus. 517, 542 (2000).
389 See Allen, supra note 98, (citing comments by Annette Dickinson, the president of the
Council for Responsible Nutrition).
390 See Packer-Tursman, supra note 379 (citing comments by David Schardt, senior nutritionist
at the Center for Science in the Public Interest).
391 Similar false deductions often arise with "green" symbols indicating that a product is
somehow environmentally-friendly. Many times, those products either offer no meaningful
environmental benefit or are based deceptively on half-truths. See generally Roger D. Wayne, The
Emperor's New Eco-Logos?: A Critical Review of the Scientific Environmental Report Card and the
Green Seal Certification Mark Programs, 14 VA. ENVTL. L.J. 51 (1994).
392 See Douglas A. Kysar, Preferences for Processes: the Process/Product Distinction and the
Regulation of Consumer Choice Preferences, 118 HARV. L. REV. 525, 626-27 (2004).
393 See Uli Schmetzer, Australia Recalls Diet Supplements, CHI. TRIB., May 2, 2003, at C4.
394 See Packer-Tursman, supra note 379.
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only those products which pass sufficiency standards-meaning that products
presenting the greatest danger and inefficacy remain unknown to consumers. Of
greater concern, watchdogs may afford preferential treatment to supplier partners
and fail to disclose this influence when posting results. For instance, in February
2005, the Council for Responsible Nutrition urged the FTC to investigate whether
ConsumerLab.com intimidates supplement manufacturers into paying for its services
to avoid less favorable results.
Likewise troubling, self-policing among dietary supplement manufacturers often
proves inadequate and unpredictable. This is particularly apparent given the wide
variances among industry participants, with manufacturers possessing disparate
incentives depending on size and diversity of product line. 395 Accordingly, while a
number of large, established dietary supplement manufacturers produce multiple
product types, including pharmaceuticals and over-the-counter medicines, smaller
operations have limited resources for testing and greater desire for "the quick
buck. 396 Given such market heterogeneity, negotiating common guidelines tends to
prove difficult, thus diminishing the potential for consumer elucidation.397
V. MAXIMIZING CONSUMER CHOICE & AUTONOMY FOR DIETARY
SUPPLEMENT CONSUMPTION
As explored in this Article, existing legal frameworks encourage the distribution
of indeterminable dietary supplements into the same stream of commerce as safe and
effective dietary supplements, as well as FDA-approved drugs and food products.
Peculiarly, despite incalculable enhancements in testing and information-sharing
technologies, lawmakers treat dietary supplements much like they were treated by
the Pure Food and Drugs Act of 19069, which likewise placed the burden on the
federal government to discover dangerous product ingredients, and which likewise
offered scant incentive for voluntary disclosure of adverse health-related
phenomena.39 9  This is of particular concern, since consumers significantly
undervalue the ease with which dietary supplements may enter the market and the
extent of damage such supplements must cause before governmental actors may
legally intervene. Moreover, because of cognitive biases, certain population groups,
including the young and the economically-disadvantaged, excessively underestimate
the relevant risks of dietary supplement consumption. Only further disrupting
consumer perception, market participants often manipulate these biases through
misleading advertising and erroneous product labeling. Although private
enforcement mechanisms offer marginal deterrence to deviant market behavior, they
tend to lack the thrust and consistency of effective government regulation found in
other realms of food and drug law.
395 See Shari Roan, Recall of 2 Products Points Up Risk of Using Supplements, L.A. TIMES,
Feb. 18, 2002, at S3.396 For example, Chattem, the Chattanooga-based health and beauty aids company, produces
Ban deodorant, Icy Hot topical pain reliever, Selsun Blue dandruff shampoo, and the Dexatrim
nutrient and energy bar. See generally http://www.chattem.com/ (last visited Jan. 10, 2005); see also
Japsen, supra note, 387 (explaining difficulties of negotiations between larger supplement
manufacturers and those with short-term desire for significant revenue).
397 See Japsen, supra note 387.
398 Pub. L. No. 59-384, ch. 3915, § 2, 34 Stat. 768 (1906) (superseded by the FD&C Act in
1938).
399 Id.
COGNITIVE BIAS, MARKET MANIPULATION & CONSUMER CHOICE 259
Nevertheless, dietary supplements comprise a highly-valued and occasionally
singular product line for many consumers. Indeed, certain consumers possess
abnormally high nutritional needs, which dietary supplements can most effectively
address. 400 Likewise, consumers place significant value in the capacity to choose
health-related products, and some simply prefer "natural" substitutes to those
products supplied by the pharmaceutical drug industry, which is sometimes
criticized for price gouging. 40 1 Even when dietary supplements prove clinically
inefficacious, consumers sometimes identify immeasurable, but appreciable, holistic,
402psychiatric, and even spiritual therapeutic benefits. More abstractly, consumer
choice may be considered a positive value, and consumer capacity to select the
bundle of risks and benefits associated with supplements cannot be dismissed with
paternalistic gloves.40 3
Any optimal regulatory system for dietary supplements must thus advance two
essential, if competing, goals: 1) protect those most vulnerable from misleading
health claims and unanticipated contents; and 2) enable an informed consumer class
to purchase appreciably-beneficial products at predictable and affordable prices.
Admittedly, crafting such a framework appears uniquely challenging in light of
obvious political constraints. 40 4 However, this Article will propose two fundamental
alterations that can ameliorate consumer interaction with dietary supplements and
benefit both market participants and consumers. Indeed, in linking consumer and
industry incentives, meaningful measures may be promulgated to enhance the
interests of all affected parties.
A. LABELING REQUIREMENTS & CONSUMER CHOICE
More carefully-contemplated labeling requirements for dietary supplements
would enhance consumer risk-assessment and reward reputable supplement
manufacturers. Under current requirements, supplement manufacturers must utilize
the "Supplement Facts" panel, which divulges information on essential nutrients and
other dietary ingredients upon which a nutritional claim is based.40 5 Though the
Supplement Facts panel facilitates comparison of supplement products, it omits
consequential information for consumers, including potential interactions with
pharmaceutical drugs'and other supplements. For instance, unbeknownst to many
users, the herbal supplement St. John's Wort has been linked to organ rejection in
patients taking the drug ciclosporin. 40 6 Similarly, the Supplement Facts format fails
400 See Shalala, 504 F.2d at 789.
401 See Rhonda Kay McPherson, Pharmaceuticals: Politics, Policy & Availability, 8 GEO.
PUBLIC POL'Y REV. 25, 31 (2003); see also Abner J. Mikva, Deregulating Through the Back Door:
The Hard Way to Fight a Revolution, 57 U. CHI. L. REV. 521, 523 (describing early legislative efforts
to control pharmaceutical price gouging).
402 See supra Part lI.D.
403 See generally RICHARD H. THALER, TOWARD A POSITIVE THEORY OF CONSUMER CHOICE,
in CHOICES, VALUES, AND FRAMES 269 (Daniel Kahneman & Amos Tversky eds., 2000).
404 Indeed, even Dr. Kessler has noted that there are "certain problems you are not going to
solve" and dietary supplements are "one of them." See Gilhooley, supra note 168 (citing Marian
Burros, F.D.A. Commissioner Is Resigning After 6 Stormy Years in Office, N.Y. TIMES, Nov. 26,
1996, at Al).
405 See supra Part II.F.
406 See T.H. Breidenbach et al., Drug Interaction of St. John's Wort with Ciclosporin, 355
LANCET 1912 (2000). Also consider that herbal products are often sold as mixtures of 10 or more
different plants, vitamins, and minerals, and that such "stacking" of herbs increases the risk of toxicity
from any one of them or from interactions with each other. See Woolf, supra note 54.
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to warn of over-usage. Indeed, long-term excessive use of vitamins and minerals
might cause diarrhea, liver abnormalities, and other health ailments.40 7
These forms of information would considerably improve consumer insight,
particularly since package labeling has been found to communicate consumer
choice. Specifically, when nutritional disclosures are prominently and contextually
displayed on labels, they may significantly assist consumers in discerning
misleading suggestions from nutrient content claims, 40 8 principally linkages between
nutrient consumption and disease reduction (e.g., "low-fat diet leads reduces the
chances of cancer"). 40 9  Labeling requirements would also counter consumer
tendency to lack sufficient grasp of dietary information, particularly when assessing
desired consumption levels. 410 It is this latter lesson from the European-based
Precautionary Principle that appears particularly beneficial for American consumers.
For similar reasons, the Supplement Facts panel should be revised to express
age and gender-based "daily values" of each provided nutrient. Curiously, the
current Supplement Facts format assumes that an 18 year-old man and an 81 year-
old woman share the very same dietary needs. Indeed, consider that the daily value
for calcium is 1,000 milligrams, a figure based on the dietary needs for adults aged
31 to 50.411 Older adults, particularly older women, however, are expected to digest
significantly higher daily doses of calcium. 412 Similar defects are associated with
iron, vitamin B, and selenium daily values.413 Other daily values dramatically
overstate dietary needs. For instance, the daily values for zinc and phosphorous are
based primarily on the needs of growing teenage males and overstate the needs for
over 90 percent of the population.4 14  Consequently, dietary supplements may
mislead consumers into unappreciated purchases. This is of particular concern for
older Americans, whose cognitive biases increase the probability of optimistic
purchasing and who data suggest often view supplements as substitutes for drugs
and medicine.415
Although no label can communicate dietary information tailored for individual
consumption, perhaps a better framework would entail ranges based on age and
gender. The calcium example above appears to corroborate this idea: a range for
recommended intake based on age and gender would prove illuminating for many
consumers. Presented more effectively, nutritional labeling can diminish the effect
of misleading product advertising, a common defect of dietary supplement
407 See Andrew Martin, Panel Urges FDA Alter List of Daily Nutrients, CHI. TRIB., Dec. 12,
2003, at CI (citing research by Dr. Irwin Rosenberg, dean of the Gerald J. and Dorothy R. Freidman
School of Nutrition Science and Policy at Tufts University).
408 See J. Craig Andrews et al., Consumer Generalization of Nutrient Content Claims in
Advertising, 62 J. MARKETING 62 (1998).
409 Id. at 63.
410 See Alan S. Levy et al., Consumer Impacts of Health Claims: An Experimental Study,
Center for Food and Applied Nutrition, FDA, Jan. 10, 1997, available at
http://vm.cfsan.fda.gov/dms/hclm-toc.html; see also Marilyn Chase, Lost in Fat City: Studies Stir
Confusion Over Butter and Oils, WALL STREET J., July 10, 1995, at B I.
41 See Note, What you Need to Know about Calcium, 6 HARV. HEALTH LETTER 1 (Apr. 2003).
412 Id.; see also Squires, supra note 315 (noting that the National Institutes of Health
recommends 1,500 milligrams of calcium per day for older women).
413 See Erin O'Donnell, How to Buy the Best Vitamin, 2 NAT'L HEALTH 76 (2003) (citing
research of Dr. Jeffrey Blumberg of Tufts University, who notes that seniors and women often benefit
with higher doses of nutrients than recommended by daily values).
414 See Martin, supra note 407 (citing remarks by Dr. Irwin Rosenberg, dean of the Gerald J.
and Dorothy R. Freidman School of Nutrition Science and Policy at Tufts University).
415 See supra Part lII.C and accompanying notes.
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advertising. This would seem especially true if better instructions existed on how
to read a supplement facts label. 417 Moreover, considering the relatively low-cost of
food and drug labeling, nuanced labeling requirements would refrain from burdening
supplement companies with exacerbated production costs.
On the other hand, product labels contain limited surface areas, and
implementation of the aforementioned ideas would undoubtedly absorb greater
surface area than is currently affected by FDA regulation. Also, and not
surprisingly, when food and drug manufacturers encounter proposals that would
diminish the available label surface area for promotional language and design, they
often express fierce resistance.418 Specifically, they contend that "simplified"
required disclosures communicate the most salient information. 419 This position is
not without merit, as "information overload," whereby labels exhibit too many
warnings or data, can confuse or frustrate consumers, leading them to misinterpret or
ignore crucial information.42 ° In other words, product labels may tell more by
stating less, and thus labeling regulation must judiciously account for available
surface area.
Nevertheless, utilizing a product label to illuminate potential substance
interactions, dangers of over-usage, and age and gender-based daily values appears
not only desirable, but also compatible with supplement label surface areas. Indeed,
an unscientific survey of twenty distinct dietary supplement products reveals that
marketing and promotional information (i.e., text, graphics, artwork, claims, and
unused background) comprises approximately 60 percent to 80 percent of available
labeling space.421 Thus, at least suggestively, dietary supplement labels appear
hospitable to additional disclosure of meaningful nutritional information. For
instance, broadly defined, yet instructive age and gender based daily ranges could be
employed, such as "males between the ages of 24 and 38." These ranges could be
displayed in chart format, akin to the existing supplement facts format and thus
immediately familiar to consumers. Moreover, if disclosure of certain information
would risk information overload, a package insert could supplement labeling
information. This would seem perhaps most appropriate for potential interactions
416 See Andrews et al., supra note 408, at 72.
417 See Marian Burros, Read Any Good Nutrition Labels Lately?, N.Y. TIMES, Dec. 1, 2004, at
Fl (noting that while many Americans find food labels useful, many also struggle with utilizing all
aspects of it; Professor Burros proposes that Americans receive better education on how to observe the
facts panel).
418 See, e.g., Prepared Testimony of Al Clausi and the National Food Processors' Association
before the Senate Labor and Human Resources Committee, FEDERAL NEWS SERV., Apr. 11, 1997,
available at LEXIS News Database (concluding that proposed FDA changes to food labels would
"unnecessarily take up label space").
419 See, e.g., FDA Folic Acid Health Claim Misses Mark, CRN Says, PR NEWSWIRE, Oct. 21,
1993, available at LEXIS Newswire (citing remarks by Paul Bolar, director of regulatory affairs for
Pharmavite Corporation and chairman of Council for Responsible Nutrition's quality assurance
committee).
420 See .ayachandran N. Variyam, New Health Information is Reshaping Food Choices, I
FOOD REV. 13 (2002). This defect of product labeling is identified with pharmaceutical drug labels,
which often contain myriad disclosures in tiny font type. See generally Mark Geistfeld, Inadequate
Product Warnings and Causation, 30 U. MICH. J.L. REF. 309 (1997); see also Roberta Romano, A
Comment on Information Overload, Cognitive Illusions, and Their Implications for Public Policy, 59
S. CAL. L. REV. 313 (1986) (providing detailed analysis of information overload).
421 I measured the surface areas from labels of the following products: Advanced Whey
Protein; Centrum Performance; BCAA Plus; Universal Nutrition Amino 1900; Carb Intercept;
Centrum; Cher-Amino Protein; Cytovol; Glutamine Fuel; Glutamine Powder; Lean Max Matrix
Protein; Leptropin-Anorex; Max-Amino; Mood Factors; Muscle Mix; Perfect L-Glutamine; Power Bar
Harvest; Super Amino; Tazo Green Ginger Green Tea; and Vogi Herbal Tea.
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with pharmaceutical drugs and other supplements, where the product label could
alert the consumer of the most salient interaction and an insert could provide
supplemental data.4 2
Perhaps cognizant of these phenomena, recent court decisions have clarified the
need for nuanced health claims on supplement labels when the health claims are
based on new scientific data. 3  Namely, in Pearson, the court determined that
whenever label disclaimers can eliminate potential consumer confusion associated
with related health claims, such disclaimers-and related claims-should be
allowed.424 Accordingly, in 2003, the FDA published interim guidance procedures
("Interim Guidance Procedures"), which promote a rating system to characterize the
strength of scientific evidence that supports purported nutrient-disease relationships
on labels. 425  Most significantly, the Interim Guidance Procedures established
"qualified health claims," which are based on presumptively promising, yet
inconclusive scientific data, and which require FDA approval. It is thought that this
more nuanced approach to supplement labeling enables consumers to obtain more
timely access to critical information concerning nutrition and disease risk-
426
reduction. To date, the agency has approved three qualified health claims, one for
chopped walnuts, 427 one for omega-3 fatty acids, 428 and one for monounsaturated fat
from olive oil. 429  The long-term implications of qualified health claims are
uncertain, though if granted judiciously, they appear to facilitate the disclosure of
timely and FDA-approved label information and more carefully distinguish health
claims from structure/function claims.43°
422 This arrangement could approximate that for pharmaceutical drugs. Indeed, for particular
pharmaceutical drugs, the FDA requires that package inserts containing product information be
provided and that such inserts inform product users of the risks and benefits associated with usage.
See Mae Joanne Rosok, Direct-to-Consumer Advertising of Prescription Drugs: After a Decade of
Speculation, Courts Consider Another Exception to the Learned Intermediary Rule, 24 SEATTLE UNIV.
L. REV. 629, 638 (2000) (citing See Patient Package Inserts for Oral Contraceptives, 21 C.F.R. §
310.501 (2000); Patient Package Inserts for Estrogens, 21 C.F.R. § 310.515 (2000).
423 See FDA's Implementation of "Qualified Health Claims ": Questions and Answers, Apr.
2004, available at http://www.cfsan.fda.gov/-dms/labqhcqa.html.
424 164 F.3d 650 (D.C. Cir. 1999) (basing decision on the First Amendment and administrative
record compiled in the challenged rulemakings).
425 See FDA, Guidance for Industry and FDA: Interim Evidence-Based Ranking System for
Scientific Data & Guidance for Industry and FDA: Interim Procedures for Health Claims in the
labeling of Human Dietary Supplements (July 10, 2003), available at
http://vm.cfsan.fda.gov/-dms/hclmgui3.html.
426 See Acting FDA Commission Speaks at Council for Responsible Nutrition Annual
Conference, STATES NEWS SERVICE, Oct. 25, 2004, available at LEXIS News Wire.
427 Vendors of chopped walnuts may claim "supportive but not conclusive research shows that
eating 1.5 oz. [a little more than a handful] of walnuts per day as part of a low saturated fat and low
cholesterol diet, and not resulting in increased caloric intake, may reduce the risk of coronary heart
disease." See Sally Squires, Omega-3 Foods Can Put Benefits on Label, FDA Says, WASH. POST,
Sept. 9, 2004, at A04.
428 Products containing omega-3 fatty acids may state "Supportive but not conclusive research
shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart
disease." Id.
429 See FDA, FDA Allows Qualified Health Claim to Decrease Risk of Coronary Heart
Disease, (Nov. 1, 2004), available at http://www.fda.gov/bbs/topics/news/2004/NEWOl129.html
(noting that "There is limited but not conclusive evidence that suggests that consumers may reduce
their risk of CHD if they consume monounsaturated fat from olive oil and olive oil-containing foods
in place of foods high in saturated fat, while at the same time not increasing the total number of
calories consumed daily).
430 Others are more skeptical, however. In Center for Science in the Public Interest v. FDA,
2004 U.S. Dist. LEXIS 20781 (U.S.D.C. Sept. 17, 2004), a consumer group sued the FDA, alleging
that the Interim Guidance Procedures, in failing to comply with the procedural requirements and
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Enhanced enforcement of existing statutes can also promote communication of
label information to consumers. Indeed, many supplements list erroneous
ingredients, inaccurate estimations of certain contents, and false or misleading
claims. With more scrutinized labels, however, incentives for market manipulation
and production of dangerous products would diminish. Recent activity suggests the
FDA is increasingly engaged in such scrutiny. Notably, in United States v. Lane
Labs-USA, Inc.,431 the FDA succeeded in asserting that a company had falsely
labeled dietary supplement products as treatments for cancer and HIV.432  The
significant media attention to Lane Labs-USA, coupled with a severe sanction,433
likely deters those manufacturers contemplating label deceit.
Though less dramatic, the FDA has more regularly dispatched warning letters to
companies making false label claims about weight loss, particularly in the wake of
ephedra.434 Equally significant are the FDA's proposed revised Good Manufacturing
Practices ("GMPs") for dietary supplement companies. GMPs allow greater inquiry
into production process, raw materials, testing, and record keeping in order to
improve product quality and increase the likelihood of consistency between labels
and ingredients.435 They also offer additional means by which the FDA can pursue
436legal action against unscrupulous companies.
Increased integration between the FDA and FTC in regulating false or
misleading dietary supplement labeling would further discourage inaccurate
supplement labels. Promisingly, in December 2002, the two agencies formed a joint
enforcement task force, and they have since worked closely in challenging false
claims of supplement effectiveness for treating a range of diseases. 437 Together, they
have since brought more than 40 actions targeting fraudulently marketed
substantive standards of the NLEA, allows health claims without the requisite scientific support.
Although the case was dismissed in September 2004 for lack of standing, the manner and willingness
with which the FDA approves qualified health claims should be monitored closely to ensure sufficient
consumer protection. Similar concerns have been raised of the lack of specificity of qualified health
claims. See, e.g., Squires, supra note 427 (quoting Bruce Silverglade of the Center for Science in the
Public Interest).
431 324 F. Supp. 2d 582 (D.N.J. 2004).
432 Because of such specific health claims, the court deemed the product's marketing as
consistent with drug marketing. Thus, the product was considered an unapproved new drug with a
misbranded label. Id. at 582-84.
433 The sanction included: all inventory of these products be destroyed under FDA supervision
and Lane Labs make restitution on all sales of these products since 1999. Id.
434 See FDA Press Release, Acting FDA Commissioner Dr. Lester M Crawford Outlines
Science-Based Plan for Dietary Supplement Enforcement, Apr. 19, 2004, available at LEXIS News
Wire.
435 See Joseph A. Levitt, FDA's Plate Remains Full, LEGAL TIMES, Mar. 1, 2004, at 25.
Dietary supplement GMPs were originally enacted by DSHEA. Specifically, DSHEA amended the
FDC Act and added the dietary supplement CGMP, which deems a product "adulterated," if "it is a
dietary supplement and it has been prepared, packed, or held under conditions that do not meet current
good manufacturing practice regulations, including regulations requiring, when necessary, expiration
date labeling, issued by the Secretary under subparagraph (2). 21 U.S.C. § 342(g)(1). Subparagraph
(2) of § 342(g) provides that, "the Secretary may by regulation prescribe good manufacturing
practices for dietary supplements. Such regulations shall be modeled after current good
manufacturing practice regulations for food and may not impose standards for which there is no
current and generally available analytical methodology." 21 U.S.C. § 342(g)(2).
436 See, e.g., Nutritional Health Alliance v. FDA, 318 F.3d 92 (6th Cir. 2003).
437 See FDA, Acting FDA Commissioner Dr. Lester M Crawford Outlines Science-Based Plan
for Dietary Supplement Enforcement, (Apr. 19, 2004), available at
http://www.fda.gov/bbs/topics/news/2004/NEWO I055.html.
264 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 31 NO. 2&3 2005
supplements and other health products.438  Most recently, in November 2004, the
FTC charged three related dietary supplement companies with deceiving consumers
through deceptive advertising for their supplement products, which falsely claim to
combat weight-gain and erectile dysfunction. 439  The FTC has pledged to work
closely with the FDA to combat deceptive claims for dietary supplements.44 °
With more accurate, complete, and verifiable dietary information, consumers
can better determine the relative utility of one product over another and thus more
correctly project outcomes that result from the decision to consume particular
dietary supplements. 4 ' Such information would also diminish the effect of
cognitive tendencies to presume non-existent content benefits, as well as the related
effects of misleading advertising and distorted label claims. Equally important,
dietary supplement manufacturers would appreciate corresponding gain through
heightened labeling standards: consumer confidence in industry tends to rise when
they observe familiarity and confidence in standardized techniques.442  Although
such standards may impair the business operations of less reputable manufacturers,
they would reward more reputable manufacturers by distinguishing their products as
qualitatively superior.
B. PRODUCT REGISTRATION, ADVERSE REACTION REPORTING & CONSUMER
CHOICE
Dietary supplement manufacturers should also be obligated to register
ingredient contents with the FDA and to report adverse reactions to all products.
These two concepts are related in practice and in form and impact the veracity of
labeling claims. Under the current regulatory framework, manufacturers fail to
voluntarily reveal over 99 percent of adverse reactions reported by consumers, and
the FDA typically learns of the relatively few reported adverse-reactions too late to
prevent further harm.443 This problem is compounded by the absence of registration
438 See Prepared Statement of the Federal Trade Commission, Before the Comm. on Energy
and Commerce, Subcomm. on Oversight and Investigations, 108th Cong. (June 16, 2004), available at
http://www.ftc.gov/os/2004/06/040616dietarysupptestimony.pdf.
439 See Federal Trade Commission v. National Urilogical Group et al., Civil No. 1:04-GV-
3294, (D.G.A. Nov. 30, 2004), available at
http://www.ftc.gov/os/caselist/0223165/041130compO223165.pdf. In August 2004, the FDA also
negotiated a $1 million settlement with two dietary supplement marketers who had falsely advertised
that certain dietary supplements caused substantial weight loss without diet or exercise. See FTC
Press Release, Two Maine Dietary Supplement Marketers Pay Nearly $1 Million to Settle FTC
Deceptive Advertising Complaints (Aug. 27, 2004), at http://www.ftc.gov/opa/2004/08/pvt.htm.
440 See FTC Press Release, FTC Charges Marketers with Making Deceptive Efficacy and
Safety Claims about Ephedra and Yohimbine Dietary Supplements (Nov. 30, 2004), at
http://www.ftc.gov/opa/2004/1l/nationalurological.htm.
441 See generally JAMES R. BETTMAN, AN INFORMATION PROCESSING THEORY OF CONSUMER
CHOICE 173-228 (Addison-Wesley Publishing Co. 1979) (explaining Theory of Consumer Choice);
see also McCann, supra note 225, at 1177 (explaining consumer choice in the context of food
consumption choices).
442 See, e.g., Lauren Fisher Kellner, Trade Dress Protection for Computer User Interface
"Look and Fee", 61 U. CHI. L. REV. 1011, 1023 (1994) (describing the increase of consumer
confidence in microcomputer markets with predictable and standardized labeling mechanisms);
Thomas T. Reith Ill, Consumer Confidence: The Key to Successful E-Commerce in the Global
Marketplace, 24 SUFFOLK TRANSNAT'L L. REV. 467, 484 (2001) (noting that the EU's Organisation
For Economic Cooperation and Development finds that a combination of industry standards and
governmental legislation may lead to enhanced consumer confidence).
443 See supra Part IV.B.
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for dietary supplement products: The FDA cannot determine the ingredients of
nearly one third of the supplements for which adverse reactions are reported.444
Particularly for those vexatious ingredients that have been banned in other
countries, such as the herb aristolochia or the plant extract germander, 445 registration
would enable the FDA to more efficiently respond to any adverse reactions or,
should the FDA likewise ban those ingredients, to expedite removal of affected
products. Moreover, though it may appear unnecessary and perhaps burdensome to
require that supplement manufacturers register seemingly innocuous ingredients,
such as vitamin C or zinc, emerging scientific data can always cast doubt on prior
conclusions. Indeed, recent studies suggest that certain levels of Vitamin C
consumption might even prove harmful.446  Thus, under an optimal regulatory
framework, all supplement ingredients should be subject to registration. This
position seems particularly sensible given that ingredient registration would not
impose material costs upon manufacturers-assuming, of course, the manufacturers
are aware of their own products' ingredients.
Likewise significant, ingredient registration would enhance lines of
communication between the FDA and supplement manufacturers, as industry and
governmental actors would share product information, thus enhancing the reliability
of adverse event reporting. Such enhanced communication would also bolster recent
proposals that emphasize greater cooperation between FDA administrators and
industry actors447 and would help repair historically-strained relations between those
administrators and supplement manufacturers.448  Furthermore, ingredient
registration would follow a trend towards expanded registration of supplement
manufacturers. Indeed, the Bioterrorism Act of 2002 requires supplement
manufacturers to register location of their facilities, 449 thus enabling the FDA to
more efficiently isolate problematic ingredients and work with manufacturers on
resulting product enhancement. Similarly meaningful, manufacturing registration
allows the FDA to determine which facilities to inspect, thereby reducing
unnecessary disruption of reputable manufacturers.
Administration of adverse event reporting likewise warrants attention.
Although the FDA has recently introduced a more sophisticated adverse event
reporting system (CAERS),450 as well as pledged more thorough review of
"4 See Food Safety: Improvements Needed in Overseeing the Safety of Dietary Supplements
and "Functional Foods ", Gen. Acct. Off. Rep. No. RCED-00- 156, at 12 (July 11, 2000), available at
http://www.gao.gov/archive/2000/rcOO 156.pdf.
445 Aristolochia has been linked to kidney failure and cancer and has been banned in 10
countries. Germander has been linked to liver damage and has been banned in Germany and France.
See Twelve Supplements You Should Avoid, CONSUMER REPORTS, May 2004, available at
http://www.consumerreports.org (last visited, Feb. 15, 2005).
446 See Seon Hwa Lee, et al., Vitamin C-Induced Decomposition of Lipid Hydroperoxides to
Endogenous Genotoxins, 292 SCIENCE 2083 (2001).
447 See Chryssa V. Deliganis, Death by Apple Juice: The Problem of Foodborne Illness, the
Regulatory Response, andFurther Suggestions for Reform, 53 FOOD DRUG L.J. 681, 725 (1998).
448 See supra Part III.
"9 21 U.S.C. § 350d(a)(l) (Supp. 2002); see also Hutt, supra note 283, at 17 ("All of the
provisions in the Bioterrorism Act apply to dietary supplements and dietary ingredients as well as to
conventional foods").
450 In 2003, the FDA's Center for Food Safety and Applied Nutrition (CFSAN) established the
Center's Adverse Event Reporting System (CAERS) to monitor adverse event reports on CFSAN-
regulated products, including dietary supplements. CAERS is a computerized system that records
voluntarily received reports and separates them into product problems and adverse events. This
system unifies CFSAN's adverse event reporting through one common portal. See Statement of
Robert E. Bracket, supra note 272.
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individual dietary supplements,451 placing the burden on the agency appears
undesirable when manufacturers often enjoy optimal information at the earliest date.
This is especially true of adverse effects that are unknown at the time of marketing,
since customer complaints to the company typically emerge well before the FDA
learns of such effects. 52 Indeed, it is inefficient modeling for the FDA to expend
limited resources in pursuit of critical information which manufacturers already
453possess and can readily share. As to an applicable standard of notification, one
similar to that for pharmaceutical drugs appears sensible, at least as an initial
measure. 454  A preferable framework would thus require that supplement
manufacturers report to the FDA all serious and unexpected adverse reactions. 455
Like enhanced labeling disclosures, neither registration nor mandatory adverse
event reporting would impose substantial production costs on dietary supplement
manufacturers, and both would likely provide value to reputable manufacturers.456
Indeed, not only would notification of adverse event reporting inform manufacturers
of reactions to similar products, it may enable them to rectify problems that might
otherwise subject them to future liability.457  Equally important, these measures
would not disturb consumer access to desired products; they would likely have the
opposite effect, improving the quality and consistency of those desired products.
Moreover, by illuminating product information for the FDA, they would diminish
incentives to manipulate the market and to classify products as dietary supplements
even when such products are better classifiable as foods or medicines.
Alternatively, one might consider the privilege of the continued absence of pre-
market testing as a tradeoff for enhanced registration and adverse event reporting.
Indeed, demands for pre-market testing of dietary supplements have exploded in
recent years, both on Capital Hill 45 8 and in legal academia. 459  For dietary
supplement manufacturers, a compromise on relatively low-cost measures, including
451 See FDA, supra note 436 (Dr. Crawford outlining plans for the FDA to evaluate the
available pharmacology, published literature (including animal, in vitro, epidemiological and clinical
trial data) evidence-based reviews, and adverse event information). Id.
452 See Life Sciences Research Office, supra note 334.
453 See id. (noting how proposed changes in federal regulation of the dietary supplement
industry have spurred some manufacturers to consider their monitoring systems).
454 Imposing a more taxing standard on dietary supplement manufacturers than on
pharmaceutical drug manufacturers does not appear justified on any known evidentiary grounds. The
standard's relative stringency could be revisited, however, if it were to prove insufficient in the
dietary supplement setting.
4" 21 C.F.R. 600.80(c)(1)(i) (stating that pharmaceutical manufacturers must reveal all "serious
and unexpected" adverse reactions). This would entail that whenever a supplement manufacturers
learns of a serious and unexpected reaction (e.g., death, a life-threatening condition, inpatient
hospitalization or prolongation of existing hospitalization) from product usage, it would immediately
notify the FDA. See Michael Baram, Making Clinical Trials Safer for Human Subjects, 27 AM. J. L.
& MED. 253, 262-63 (2001) (illustrating the "serious and unexpected" standard).
456 See Colloton, supra note 163, at 549 (noting that some manufacturers complain that the
FDA fails to keep them informed of adverse reactions to their products).
457 Id.
458 See, e.g., Dietary Supplement Safety Act of 2003, S. 722, 108th Cong. (2003).
459 See, e.g., Jennifer J. Spokes, Confusion in Dietary Supplement Regulation: The Sports
Irony, 77 B.U. L. REV. 181 (1997); Leticia M. Diaz, First St. John's Wort, Now SAM-e: Is Society as a
Whole at Risk Without FDA Regulation of Psychiatric Self-Medication?, 9 KAN. J.L. & PUB. POLIY
279 (1999).
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enhanced labeling, registration, and disclosure of adverse event reporting, might
prove a feasible and far less burdensome outcome.46 °
Along these lines, required disclosure of adverse reactions was encapsulated in a
recent federal legislative proposal. The Dietary Supplement Safety Act of 2003461
("DSSA") would allow the FDA to impose the duty of postmarket surveillance on
dietary supplement companies if there is a "reasonable possibility that a use or
expected use of the dietary supplement by a significant number of consumers may
result in serious adverse experiences. 462 However, DSSA would also amend the
FDCA to require sellers of dietary supplements containing stimulants to prove the
supplements' safety before sale,463 and would remove from the definition of dietary
supplements those products promoting muscle growth and re-classify them as
anabolic steroids.464 Demand for such pre-market safety evaluations likely explains
the failure of DSSA to advance beyond its introduction. 465 As emphasized in this
Article, perhaps a more feasible and desirable method would focus on greater
disclosure of information.
VI. CONCLUSION
This Article does not advance a heavy-handed, paternalistic system that would
prevent American consumers from purchasing dietary supplements. Nor does it
discredit every dietary supplement as a product made viable by myth, ignorance, and
rabid industry deceit. Rather, in recognizing the therapeutic value of many dietary
supplements, as well as the intrinsic positive value of consumer choice, this Article
advocates supplying consumers with useful information that the market fails to
generate and thus better equipping them to make consumption decisions with
diminished cognitive bias and less affecting market manipulation. This finding
appears bolstered by data suggesting that a lack of information often leads to
consumption of products that are more "risky" and less efficacious than consumers
assume. Indeed, aligning actual risk with actual benefit would benefit any
consumption choice, particularly those choices impacting the well-being of groups
predisposed to discounting risk and over-estimating benefit.
460 See Steven P. Croley, Theories of Regulation: Incorporating the Administrative Process, 98
COLUM. L. REV. 1, 32 (1998) (explaining that compromises and trade-offs among competing groups
can yield preferable political outcomes).
461 See S. 722, 108th Cong. (2003).
462 See Proposed Section 416(c)(2)("PERIODIC ADVERSE DIETARY SUPPLEMENT
EXPERIENCE REPORTING-A manufacturer of a dietary supplement shall annually (or at such
shorter intervals as the Secretary may require), in accordance with such requirements as the Secretary
may establish, submit to the Secretary a report that discloses all information received with respect to
adverse dietary supplement experiences..."). Id. at § 416(c)(2).
463 Specifically, it would amend Chapter IV of the FDCA by adding several sections. Id.
464 Specifically, the DSSA would strike '(other than tobacco)' from the FDCA and insert
'(other than tobacco or a product that bears or contains an anabolic steroid (including a substance that
is chemically and pharmacologically related to testosterone but not including an estrogen, progestin,
or corticosteroid)).' Id. at § 4.
465 The dietary supplement lobby, along with various holistic medicine groups, have deftly
employed fear tactics to stymie legislative progression. Indeed, consider comments by the National
Nutritional Foods Association: "[DSSA] would subject nearly all vitamins, minerals, herbal products
and other supplements to a level of scrutiny that is both unwarranted and unnecessary. Products that
have been used safely for hundreds-and in some cases, thousands-of years would be subject to
clinical evaluation using standards that are at the complete discretion of the FDA. Oppose this
Legislation!" See Healing Earth Resources, The Dietary Supplement 'Safety' Act, at
http://www.healingearthresources.com/site/epage/ 11711 163.htm (last visited, Jan. 1, 2005).
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Moreover, to the extent that an element of paternalism exists in this Article, it is
carefully couched. By advocating low-cost informational mechanisms instead of
product prohibition, this Article recognizes the dangers of safety regulations where
the collateral risks likely outweigh the proposed risk reduction.466 At the same time,
the proposals indicated in this Article would scarcely burden reputable supplement
manufacturers while vastly securing industry practices, thereby diminishing the
prevalence of tort liability. Accordingly, utilizing enhanced informational channels
to align the interests of consumers, the FDA, and reputable supplement
manufacturers appears universally beneficial.
Admittedly, the proposals in this Article should not be considered panaceas to a
deeply flawed dietary supplement industry. Other, more dramatic ideas, including
pre-market FDA approval and re-classification of certain supplements as drugs, may
offer substantial benefit to consumers. However, these ideas also run the risk of
over-bearing governmental intrusion, where the benefit of consumer safety proves
outweighed by diminished consumer choice and disturbed price scheming,
particularly with a pharmaceutical drug industry that already sets prices too high for
many Americans. Indeed, this Article does not propose a "zero-tolerance rule" for
any dietary supplement; rather, it features proposed FDA discretion that would
advance flexibility and cooperation with industry.467 Similarly, by legitimizing
supplements in relation to their risks and benefits, the proposals in this Article would
discourage unnecessary regulatory cost and delay. At the same time, by forcing
supplement manufacturers to accurately reveal benefit and risk, these proposals
would presumably discourage initial investment by less reputable manufacturers,
thus improving consumer confidence in remaining industry participants.
At some point in the future, more dramatic measures to protect dietary
supplement consumers may prove desirable. Before contracting consumer choice,
however, it appears sensible to attempt consumer enlightenment.
466 For an excellent discussion on paternalism and the drug approval process, see Michael D.
Greenberg, Information, Paternalism, and Rational Decision-Making: The Balance of FDA New Drug
Approval, 13 ALB. L.J. SCI. & TECH. 663, 674-77 (2003).
467 See STEPHEN BREYER BREAKING THE VICIOUS CIRCLE: TOWARD EFFECTIVE RISK
REGULATION 11 (1993) (noting that policies which encourage automatic removal of asbestos from
buildings-regardless of the amount of asbestos-can cause more damage than asbestos itself).
